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1.1 Gene therapy 
Gene therapy is a clinical approach to treat diseases and correct disorders at a genetic level. 
Historically, this approach has been used to treat genetic disorders, but after several 
advancements in the field of genetic engineering, it is also possible to cure acquired diseases, 
cancer and infections. Such a therapy would restore proper functioning of the diseased organ 
or tissue. The main objectives of gene therapy are expression of a deficit gene, knockdown of 
an over-expressing gene, or replacement of a defective gene in considerable number of target 
cells.  Gene therapy can be performed ex vivo which involves isolation of cells isolated from 
patients, introduction of genetic material using suitable vectors and injecting back into the 
patients. Alternatively, in in vivo gene therapy, the patient is directly injected with vectors 
containing genetic material [1].  Over years, gene therapy has garnered interest from researchers 
in various fields. A lot of progress has been made in the development of viral and non-viral 
vectors for gene therapy [2].  
 
In the plethora of gene delivery strategies available today, internalisation of the delivery 
vehicle, protection of its cargo against degradation in the extracellular milieu, and its 
subsequent release are the major factors determining the success of the treatment regimen. 
Nucleic acids such as DNA (especially plasmid DNA) and siRNA have long been experimented 
with for the treatment of a comprehensive range of diseases [3].  
 
To achieve the desired effect, nucleic acids need to be delivered into the cells bypassing various 
hindrances [4]. Of these, blood is a major barrier due to its complexity in terms of composition 
followed by cellular entry by bypassing the cell wall. Once the delivery vehicles enter the cells, 
they need to withstand the endosomal and lysosomal environments. This can only be achieved 
with delivery vehicle designed to sustain the extracellular and intracellular environments. 
Numerous factors such as cytotoxicity, cell penetrability, degradation and intracellular 
dissociation of the delivery vehicles are responsible for a reliable therapy. Viral vectors which 
fulfil the above requirements, have been employed in the past and have also shown some 
promising results in vivo [5-7]. Unfortunately, after a series of clinical trials their use was 
frowned upon owing to their toxic side effects, risk of undesired immune reactions, harmful 
mutations and cost of treatment [8-10]. Subsequent focus was hence laid upon development of 
alternatives to viral vectors for in vitro, in vivo and ex vivo delivery.  
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Among others, liposomes, polymers and nanoparticles have been the most studied non-viral 
vectors for gene therapy. With the aspect of achieving the delivery efficiency similar to viruses, 
in this work, focus was laid upon developing hybrid vectors utilising physical means to enhance 
the gene transfer.  
 
1.2 RNA interference 
Majority of the gene delivery strategies involve addition of a specific functionality to the target 
organ or tissue to overcome its deficiencies. With the discovery of gene silencing ability of 
short interfering RNA (siRNA) by Fire and Mello in 1998, new horizons were opened in the 
field of gene therapy [11]. siRNA’s ability to knock down the production of corresponding 
proteins is known as RNA interference (RNAi). The mechanism with which siRNA works is 
through a multiprotein RNA induced silencing complex (RISC). After entering a cell, double 
stranded siRNA is unwound into two single strands by the RISC complex. Of these two strands, 
the guide strand remains bound to the complex which acts as template to its complementary 
mRNA. Upon recognition of the complementary mRNA, Argonuate (AGO), a protein found in 
the RISC complex, cleaves the mRNA inhibiting protein translation ( 
Figure 1) [12, 13].  
 
While DNA’s can go up to several kilo base pairs (bp), siRNA is a relatively small biomolecule 
comprising 21-23 bp. A new class of 27-mer siRNA termed dicer-substrate siRNA (dsiRNA) 
having a dicer sequence has been found to be more efficient. dsiRNA works by mimicking the 
features of naturally occurring dicer substrates thereby promoting an efficient incorporation 
into the RISC complex [14, 15]. Due to its small size, siRNA is highly susceptible to enzymatic 
degradation, necessitating the use of an appropriate delivery system [16].  
 
 4 
 
 
 
Figure 1: Graphical illustration of the RNA induced silencing complex  
 
1.3 Non-viral Vectors 
The success of non-viral gene therapy depends on the application form or the delivery vehicle. 
An ideal delivery vehicle should possess significant delivery efficiency and should be relatively 
non-toxic and biocompatible. Delivery of nucleic acid devoid of vectors i.e. naked nucleic acid 
delivery has been employed with varying success. The commonly used methods for naked 
delivery are electroporation, micro needle injection and ballistic delivery which are all limited 
to an in vitro set up and have never made their way into clinical therapeutics [17]. On the other 
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hand, delivery of nucleic acids using delivery vehicles such as liposomes, polymers and 
nanoparticles has been met with considerable success [18-20]. 1,2-dioleoyl-3-
trimethylammonium-propane (DOTAP), 1,2-di-O-octadecenyl-3-trimethylammonium propane 
(DOTMA), (1-[2-(9-(Z)-octadecenoyloxy)ethyl] -2-(8-(Z)-heptadecenyl) -3 (hydroxyethyl) 
imidazolinium chloride (DOTIM), N-methyl-4(dioleyl)methylpyridiniumchloride (SAINT), 
1,2-dimyristyloxy-propyl-3-dimethyl-hydroxy ethyl ammonium bromide (DMRIE), 1,2-di-
(9Z-octadecenoyl)-sn-glycero-3- [(N- (5-amino-1-carboxypentyl) iminodiacetic acid) succinyl 
(DOGS), and 1,2-dioleoyl-sn-glycero-3-phosphoethanolamine (DOPE) are the most frequently 
used lipids for delivery of nucleic acids [21, 22]. Among polymers, polyethylenimine (PEI; 
linear and branched) of various molecular weights, poly-L-lysine (PLL), chitosan, 
polyamidoamine (PAMAM) are widely used [23, 24]. Poly (lactic-co-glycolic acid) (PLGA) 
and silica particles have been proven to be indispensable for formulation of nanoparticles for 
gene delivery [20]. Several therapies which are under clinical evaluation are based upon one of 
these vectors [25]. 
 
Size, surface charge, stability and rigidness are the main factors influencing the delivery 
efficiency of non-viral vectors [26]. These parameters laid the foundation for this study which 
was aimed at developing a non-viral vector system capable of effectively delivering the genetic 
material with minimal effects on cell viability. 
 
1.4 Liposomes  
Though it has been more than a century since their first mention by Otto Lehmann in his book 
‘Die Flüssige Kristalle’, it wasn’t until the 60’s, where Alec Bangham along with his colleagues 
at the Babraham Institute, discovered the beneficial properties of liposomes [27]. Since then, 
several research groups have been involved in studying liposomes from structure to interactions 
with biological systems.  
 
Based on their lamellarity, liposomes may be classified into two major groups, multilamellar 
and unilamellar vesicles; unilamellar liposomes are further divided into small and large 
unilamellar vesicles [28]. Simple as they might seem, many factors come into play in the 
formation of a liposome. Physicochemical factors such as van der Waals forces, phase transition 
temperature, chemical composition of the lipids used, solvents employed, rehydration buffers, 
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pH, presence or absence of inorganic salts etc. all play a vital role in shaping a liposome [21, 
29, 30].   
 
Liposomal delivery of drugs and nucleic acids is an evolving field comprising of several 
research disciplines ranging from biophysics to medicine. Hydrophilic, hydrophobic, 
amphiphilic substances, antibodies, and genetic material can be delivered using liposomes 
(Figure 2). 
 
 
 
 
Figure 2: Illustration of a liposome with different types of cargo [31]  
 
Formulation of an optimal liposomal delivery system requires knowledge in various fields like 
physical, analytical, organic and colloidal chemistry, theoretical, structural and surface physics, 
physiology, pharmacology, pharmacokinetics and toxicology to name a few [32]. An ideal 
liposomal delivery system should be able to deliver its cargo to the target organ with minimal 
loss and without being immunogenic. In practice, this is an extremely challenging task to 
achieve considering the complexity of the biological fluids which pose a major challenge 
between their administration and reaching of the therapeutic target.  
 7 
 
Among the biological fluids, blood plays a pivotal role in determining the fate of the liposomes. 
Plasma, which makes up 55 % of blood‘s volume, consists of numerous ions, proteins, lipases, 
glucose, antibodies, salts, vitamins and amino acids which all interact with the liposomes and 
are detrimental to its stability [33].  
 
Upon reaching their target, liposomes interact with the cells of the target tissue or organ, which 
forms the basis for the therapy. There are many ways in which liposomes interact with cells viz. 
intermembrane transfer i.e. transfer between the phospholipid bilayers of the cells and 
liposomes; contact release, which is the release of the aqueous contents of the liposome upon 
cellular contact due to an apparent increase in the permeability of the liposomal membrane; 
adsorption; cellular fusion, in which liposomes and cell membranes fuse together; phagocytosis 
and endocytosis [34-38]. The size, shape, surface charge and composition of the liposomes are 
the determining factors for cellular interactions and uptake.  
 
Due to similarities in composition with biological membranes and ease of optimisation, 
liposomes make a popular choice for delivery of drugs and genetic material. Biocompatibility, 
bioavailability, circulation time and solubility of the cargo can be improved using liposomes. 
Depending upon their application, either cationic, anionic or zwitterionic lipids maybe 
employed in liposomal formulation [39-41]. Due to their electrostatic interactions with nucleic 
acids, cationic liposomes are the first choice for gene delivery [42-44]. However, without 
appropriate shielding of the surface charge, cationic liposomes tend to be cytotoxic and have 
low storage stability [45-47].  
 
On the other hand, anionic liposomal formulations tend to be less cytotoxic and when 
formulated using zwitterionic phospholipids (e.g. Dipalmitoylphosphatidylcholine; DPPC) and 
helper lipids (e.g. DOPE and cholesterol), offer more room for optimisation in terms of surface 
charge and mechanical stability which have a significant effect on endosomal escape and 
binding of nucleic acids [48-51]. With cytotoxicity, delivery efficiency, stability being the 
driving forces, this study was directed to develop a novel formulation wherein emphasis was 
laid upon controlled release of the liposomal contents. 
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1.5 Polymers 
Cationic polymers have a long-standing history in gene delivery. Most of the cationic polymers 
rely on the ability of the amines to protonate in physiological environment which 
electrostatically attracts the oppositely charged phosphate groups of nucleic acids to form nano-
complexes or polyplexes [52, 53].  
 
Beginning with PLL, research into cationic polymers as condensing and gene transfer agents 
has made many breakthroughs [54, 55]. Worth mentioning is PEI which has set a gold standard 
as a transfection agent after its beneficial properties as a gene transfer agent were realised. PEI 
has a high charge density which condenses the nucleic acids and protects them against nucleases 
(Figure 3) [56]. Though the exact mechanism of action is still debated, the endosome rupturing 
‘proton-sponge effect’ has been proposed as the main mode of action [57]. During endosome 
maturation, the pH inside begins to acidify. Starting with early endosome at around 6, the pH 
falls to 5 in late endosomes, this fall in pH protonates the secondary and tertiary amines of PEI 
which causes increased influx of protons. This increases the osmotic pressure leading to 
swelling and eventual rupture of the endosome [58, 59].   
 
 
 
Figure 3: Representation of a cationic polymer-PEI based polyplex 
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Since the discovery of its ability to condense genetic material, PEI has been the most studied 
polymer in gene therapy [60-62]. Various modifications such as grafting, coupling, cross-
linking, PEGylation have been done to improve the transfection efficiency of PEI and to reduce 
its cytotoxicity [63-70].  
 
Soon after PEI, other synthetic polymers like PAMAM, PLL, poly (2-dimethylaminoethyl 
methacrylate) (pDMAEMA) and naturally occurring polymers such as chitosan made their way 
into gene delivery [71-74].  
 
1.6 Composite liposome-polymer lipopolyplexes 
Utilising the biocompatible property of liposomes and combining it with the (nucleic acid) 
condensation and protective properties of cationic polymers, a hybrid delivery vehicle has been 
developed. The combination of cationic polymers and liposomes have shown promising 
transfection and knockdown efficiencies in vitro [75]. Since the cell membrane is also 
composed of phospholipids, encapsulation of cationic nanoparticles in phospholipid based 
liposomes enhances the biocompatibility [76].  
 
A deacylated variant of linear PEI (lPEI) was used to prepare the polyplexes used in the study. 
Deacylation dramatically improves transfection efficiency and the absence of primary amines 
in linear PEI renders it less cytotoxic than its branched counterpart [77]. The primary amines 
are responsible for the higher charge density of branched PEI (bPEI) which is often associated 
with destabilisation of cell wall and cellular necrosis [78-80].  
 
Using lPEI, several formulations were developed to simplify the design of the complexes and 
to improve transfection efficacy and cytotoxicity. Due to their cationic nature, lPEI/nucleic acid 
complexes often invoke immune responses [79]. To shield the cationic charge and to address 
the most frequent problem with polyplexes i.e. aggregation, polyplexes were encapsulated with 
various liposomal combinations using DPPC, DOTAP, DOPE, and cholesterol to form 
lipopolyplexes.  
 
When liposomes are added to nucleic acid-polycation complexes, an extensive reorganisation 
of the lipid membranes takes place following the initial contact, resulting in polymer-nucleic 
acid complexes with lipid coatings (Figure 4). This strategy overcomes the surface charge issue 
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associated with cationic polymers. The extracellular cytotoxicity of the complexes is reduced, 
making room for receptor-mediated targeting without interference of nonspecific charge-charge 
interaction. 
 
 
 
 
 
Figure 4: Illustration of lipopolyplex formation 
 
 The transfection efficiency of gene delivery vehicles depends upon their surface charge, size, 
rigidity and stability, especially in the physiological environment [26, 81]. A unique 
combination of lipids was therefore selected for formulation of lipopolyplexes. To obtain the 
desired physicochemical characteristics, viz. slight positive charge and a size range in between 
100 and 200 nm along with improved stability, helper lipids were incorporated into the 
liposomal formulations. These have a considerable influence on the electrostatics, lipid self-
assembly, level of hydration, packing parameter and surface charge [21, 82]. DOPE and 
cholesterol were chosen as helper lipids after a series of experiments. The most common 
problem faced by gene delivery vehicles is the escape of the delivery vehicle from the endosome 
and other cellular compartments [83]. To tackle this problem, focus was laid upon physical 
methods for enhancement of gene transfer in this thesis work. Light and ultrasound have been 
used as the preferred methods due their minimally invasive nature.  
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1.7 Photo activation 
Light has been used since ages as a therapeutic agent in ancient Indian and Egyptian 
civilisations for the treatment of psoriasis, vitiligo, rickets and skin cancer [84]. Photodynamic 
therapy (PDT) is a process which induces localised tissue necrosis. An otherwise inert 
photosensitiser delivered to the target tissue is activated using light of a specific wavelength. In 
presence of molecular oxygen, reactive oxygen species are generated which selectively destroy 
the tumour tissue [85, 86]. PDT has been approved by the European medicines agency (EMA) 
and Food and drug administration (FDA) for the treatment of certain pre-malignant and 
malignant diseases [87-89]. Photo-chemical internalisation (PCI) is a subclass of photodynamic 
therapy wherein light is used to trigger breakdown of the endo/lysosomal membranes  
(Figure 5). This process is based on photosensitisers localised inside these membranes. Photo-
activation initiates photochemical reactions, causing rupture of the vesicles leading to release 
of endocytosed compounds [90-93]. PCI could be used for both triggered release of substances 
and biomolecules and for enhancing the therapeutic efficacy [94-96]. PCI strategy has been 
successfully utilised for enhancing the release of polymer-DNA complexes [97, 98]. For 
enhancing the endosomal release, liposomes containing curcumin, a proven therapeutic agent 
and a photosensitiser, were used for the lipopolyplex formulation. 
 
 
Figure 5: PCI; Endosomal rupture and subsequent release of contents following irradiation 
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1.8 Ultrasound  
Since its inception in the late 50’s, ultrasound has made countless breakthroughs in the field of 
medical diagnostics. It is a gentle and non-invasive tool which has been proven valuable in the 
diagnosis of a variety of diseases [99]. Ultrasound has excellent patient compliance and a 
remarkable safety track record [100, 101]. Nanocarriers have been successfully employed in 
ultrasound mediated drug delivery and as theranostic agents for enhancing ultrasound contrast 
[102-104]. The use of ultrasound in gene transfer, termed as ultrasound enhanced gene transfer 
(UEGT), began after individual research groups observed enhanced permeation of delivery 
vehicles into the cell and subsequent release [105, 106]. It is a known fact ultrasound 
permeabilises the cell membrane which is the underlying mechanism of ultrasound enhanced 
cellular uptake of nanocarriers [107]. Among others, gas-filled microbubbles are the most 
commonly used delivery vehicles for UEGT [108, 109]. Upon application of ultrasound, these 
bubbles blast and the propulsion created from this effect enhances their delivery into the cells. 
Enhancement of liposomal gene delivery using ultrasound has already been reported, the exact 
mechanism of action is however, still unclear.  
 
1.9 Anti-Inflammatory gene therapy 
Advancements in RNAi research have paved a new dimension in therapeutic targets for gene 
delivery, which was otherwise confined to transfer of therapeutic genetic material for replacing 
defective genes. RNAi has provided a means of downregulating expression of various 
overexpressed genes [110]. The therapeutic aspects of RNAi have extended to treatment of anti-
inflammatory disorders [111]. E-selectin is expressed by the SELE gene in humans. It is 
responsible for inflammatory activity in endothelial cells and mediates the adhesion of tumour 
cells to the endothelial cells thereby playing a major role in tumour metastasis [112, 113]. 
Delivery vehicles loaded with siRNA directed against SELE can mediate knockdown of E-
selectin thereby inhibiting inflammatory activity and tumour cell metastasis [114]. 
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Aims and scope 
This work was aimed at developing non-viral vectors for anti-inflammatory gene therapy 
capable of overcoming the extracellular and cellular barriers. The ambit of this study included 
development of a potent multicomponent delivery system with low cytotoxicity without 
compromising on delivery efficiency.  
 
The key aspects covered in this work include: 
 
▪ Designing a delivery system capable of dealing with the shortcomings of non-viral vectors 
- A relatively low toxic vehicle with high gene transfer efficiency 
▪ Optimising the parameters determining the physicochemical properties of the 
lipopolyplexes 
▪ Detailed physical characterisation of the lipopolyplexes in terms of structure and 
morphology 
▪ Electron microscopic elucidation of the polyplex-in-liposome structure  
▪ Establishing a reproducible method for preparation of lipopolyplexes and transfection 
▪ Determination of the mechanism of cellular uptake 
▪ Physically enhancing gene transfer by improving endosomal escape of the lipopolyplexes 
using light and ultrasound  
▪ Selective knockdown of the inflammatory gene SELE by means of RNAi. 
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Part II: Experimental 
 
 
 
 
 
 
 
 
 
 15 
 
2.1 Materials 
List of materials 
 
Materials or substances Source 
 15 mm cover slips Gerhard Menzel B.V. & Co. KG., 
Braunschweig, Germany 
0.2 µm PES Syringe Filters Whatman plc, Buckinghamshire, UK 
0.2 cm Electroporation Cuvettes Bio-Rad Laboratories GmbH, Munich, 
Germany 
10 kDa MWCO Centrifugal Concentrators; 
Vivaspin 6 
Sartorious Stedim GmbH; Göttingen, 
Germany 
12-well plates; Nunclon Delta Nunc GmbH & Co. KG., Wiesbaden, 
Germany 
2-iminothiolane hydrochloride; Traut’s 
Reagent 
Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
3,3’,5,5’-Tetramethylbenzidine Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
96-well microtiter plates; CytoOne®  Starlab International GmbH, Hamburg, 
Germany 
A549 cell line ATCC®, Manassas, USA 
Adhesive plate seals Boehringer Mannheim GmbH, 
Mannheim, Germany 
AFM Probe; HQ:MSC16/Al BS µmasch, Tallinn, Estonia 
Agar Merck KGaA, Darmstadt, Germany 
Agarose Merck KGaA, Darmstadt, Germany 
Ampicillin Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Anti-human E-selectin monoclonal antibody Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Anti-luc siRNA 1 GE Dharmacon, Lafayette, USA 
Argon Ion Laser; Enterprise II Coherent Inc., Santa Clara, USA 
Atomic force microscope; Nanowizard® 1 JPK Instruments AG, Berlin, Germany 
Autoclave, Tuttnauer 3850 ELC Tuttnauer GmbH, Linden, Germany 
Bath Sonicator; Transonic Digital S Elma Schmidbauer GmbH, Singen, 
Germany 
Beetle luciferin Synchem UG & Co. KG, Felsberg, 
Germany 
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Carbon Tabs PLANO GmbH, Wetzlar, Germany 
CCD-Camera; Gatan MegaScan 794 Gatan Inc., Pleasanton, USA 
Cell Culture Lysis Reagent Promega GmbH, Mannheim, Germany 
Centrifuge; Beckman J2-21 Beckman Coulter GmbH, Krefeld, 
Germany 
Specific Pathogen Free Eggs Valo Biomedia GmbH, Osterholz-
Scharmbeck, Germany 
Chlorpromazine Alfa Aesar GmbH & Co. KG., Karlsruhe, 
Germany 
Cholesterol Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
CO2 incubator, HeraCell Heraus GmbH & Co. KG., Hanau, 
Germany 
Coagulation analyser; Coatron M1 Teco GmbH, Neufahrn, Germany 
Confocal laser scanning microscope; LSM 
510/Axiovert 100M 
Carl Zeiss Microscopy GmbH, Jena, 
Germany 
Critical Point Dryer; Bal-Tec CPD 030 Bal-Tec AG, Balzers, Liechtenstein 
Cryo Transfer System; Alto 2500 Gatan Inc., Pleasanton, USA 
Culture Tubes; Pyrex Corning Inc., Corning, USA 
Curcumin Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
DAPI Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Digital image acquisition system; DISS 5 Point Electronic GmbH, Halle, Germany 
DMEM-HG Biochrom GmbH, Berlin, Germany 
DMEM-LG Biochrom GmbH, Berlin, Germany 
DNA ladder; GeneRuler 1 kb Fermentas Life Sciences, Vilnius, 
Lithuania 
DMSO; ≥ 99 % Acros Organics B.V.B.A., Geel, Belgium 
DOPE Lipoid GmbH, Ludwigshafen, Germany 
DOTAP Avanti Polar Lipids Inc., Alabaster, USA 
DPPC Lipoid GmbH, Ludwigshafen, Germany 
Dynasore Cayman Chemical Company, Ann Arbor, 
USA 
EA.hy926 cell line ATCC®, Manassas, USA 
Electrophoresis chamber; Thermo Hybaid 
Electron 4 
Thermo Electron GmbH, Ulm, Germany 
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Electroporator; Gene Pulser™ Bio-Rad GmbH, Munich, Germany 
Endothelial cell growth kit; PCS-100-041™ ATCC®, Manassas, USA 
Ethanol Carl Roth GmbH + Co. KG., Karlsruhe, 
Germany 
Ethidium Bromide Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Extruder; Avanti Mini Avanti Polar Lipids Inc., Alabaster, USA 
Field emission SEM; JSM-7500F JEOL Ltd., Tokyo, Japan 
Filipin III Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Foetal bovine serum PAA Laboratories GmbH, Cölbe, 
Germany 
Formaldehyde Alfa Aesar GmbH & Co. KG., Karlsruhe, 
Germany 
Freeze Drier; Christ Beta I Martin Christ Gefriertrocknungsanlagen 
GmbH, Osterode am Harz, Germany 
Glow Discharger; Edwards S150B Edwards Vacuum, Crawley, UK 
Glutaraldehyde Alfa Aesar GmbH & Co. KG., Karlsruhe, 
Germany 
Gold Nanospheres Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Hatching incubator; Ehret KMB 6 Dipl. Ing. W. Ehret GmbH, 
Emmendingen, Germany 
HeLa cell line Clontech Laboratories Inc., Saint-
Germain-en-Laye, France 
Heparin AppliChem GmbH, Darmstadt, Germany 
Human E-selectin standard Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
IMDM Biochrom GmbH, Berlin, Germany 
INTERFERin® Polyplus-transfection® SA, Illkirch, 
France 
Isotonic NaCl B.Braun Melsungen AG, Melsungen, 
Germany 
Escherichia Coli; JM109 Clontech Laboratories Inc., Saint-
Germain-en-Laye, France 
Kanamycin Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
L929 ATCC®, Manassas, USA 
Laminar Flow Hood; Labgard Class II NuAire Inc., Plymouth, USA 
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LDH assay Kit Roche Diagnostics AG, Basel, 
Switzerland 
LED Irradiator Lumundus GmbH, Eisenach, Germany 
Liquid CO2 Praxair Deutschland GmbH, Düsseldorf, 
Germany 
Constant Power Supply; LKB 2197 LKB Produkter AB, Bromma, Sweden 
Luciferase GL3 duplex Dharmacon Inc., Lafayette, USA 
Magnetic Stirrer; MCS 66 CAT Scientific, Paso Robles, USA 
MCDB 153 Biochrom GmbH, Berlin, Germany 
Medical ultrasound device; eZono® 3000  eZono AG, Jena, Germany 
Micro reagent tubes Sarstedt AG & Co., Nümbrecht, Germany 
MilliQ® Water Millipore Corporation, Billerica, USA 
Mounting medium; FluorSave™  Calbiochem Corporation, San Diego, 
USA 
MTT dye Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
N-2-Hydroxyethylpiperazine-Nʹ-2-
ethanesulfonic acid; HEPES ≥ 99 % 
VWR International GmbH, Darmstadt, 
Germany 
Osmium Tetroxide Alfa Aesar GmbH & Co. KG., Karlsruhe, 
Germany 
pCMV-luc PlasmidFactory GmbH & Co. KG., 
Bielefeld, Germany 
PCS-100-012™ cell line ATCC®, Manassas, USA 
pEGFP-N1 Clontech Laboratories Inc., Saint-
Germain-en-Laye, France 
PEI MAX; Linear PEI 22 kDa Polysciences Europe GmbH, Hirschberg, 
Germany 
Petri Dishes; Tissue Culture grade and 
Suspension type 
Sarstedt AG & Co., Nümbrecht, Germany 
Piece BCA assay kit Thermo Fisher Scientific GmbH, 
Dreieich, Germany 
Plasmid Isolation Kit; QIAfilter Giga Qiagen GmbH, Hilden, Germany 
Polycarbonate membranes Whatman plc, Buckinghamshire, UK 
Polymin®; Branched PEI 25 kDa BASF AG, Ludwigshafen, Germany 
RNAse free water GE Healthcare Europe GmbH, Freiburg, 
Germany 
Rotary Evaporator; Laborota 4000 Heidolph Instruments GmbH & Co. KG., 
Schwabach, Germany 
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Scanning electron microscope; Hitachi S-510 Nissei Sangyo Co. Ltd., Tokyo, Japan 
SELE dsiRNA 27mer OriGene Technologies, Rockville, USA 
SELE siRNA Santa Cruz Biotechnology Inc., Santa 
Cruz, USA 
SEM Specimen Stubs PLANO GmbH, Wetzlar, Germany 
Shaking Incubator; IKA KS4000 IC IKA Werke & Co. KG., Staufen, 
Germany 
siRNA dilution buffer GE Healthcare Europe GmbH, Freiburg, 
Germany 
siRNA No. 2; siCtrl Dharmacon Inc., Lafayette, USA 
SK-OV-3 cell cline ATCC®, Manassas, USA 
SK-OV-3-luc cell line Gift from Prof. Dr. Aigner 
Microscopy Slides Gerhard Menzel B.V. & Co. KG., 
Braunschweig, Germany 
SOC Carl Roth GmbH + Co. KG., Karlsruhe, 
Germany 
Sodium citrate Eifelfango Werk GmbH & Co. KG., Bad 
Neuenahr-Ahrweiler, Germany 
Luminometer; FLUOstar® Optima BMG Labtech, Ortenberg, Germany 
Spectrophotometer; Ultrospec 3000 Pharmacia Biotech AG, Uppsala, Sweden 
Sputter Coater; Edwards S150 Edwards Vacuum, Crawley, UK 
TEClot aPTT-S Kit Teco GmbH, Neufahrn, Germany 
TEM 300 mesh grids PLANO GmbH, Wetzlar, Germany 
Trans-Illuminator; BioDoc Analyse Ti5 Whatman Biometra GmbH, Göttingen, 
Germany 
Transmission electron microscope; JEM-3010 JEOL Ltd., Tokyo, Japan 
Tris Merck KGaA, Darmstadt, Germany 
Triton™ X-100 Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Uranyl acetate Sigma Aldrich Chemie GmbH, 
Taufkirchen, Germany 
Vacuum Pump; SC 920 KNF Neuberger GmbH, Freiburg, 
Germany 
Water Bath Kottermann GmbH & Co. KG., Hänigsen, 
Germany 
White opaque 96-well plates Brand GmbH + Co. KG., Wertheim, 
Germany 
Zetasizer Nano ZS Malvern Instruments Ltd, Malvern, UK 
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2.1.1 Lipids 
2.2.1.1 DPPC 
Dipalmitoylphosphatidylcholine is a fatty acid containing a polar phosphate head group and a 
nonpolar fatty acid chain. DPPC is an amphiphilic molecule with a molecular weight of 734.039 
g/mol and a phase transition temperature Tc of 41 °C. The molecules of DPPC can arrange in 
favour of polar and nonpolar interactions to a phospholipid bilayer which can form spherical 
vesicles [115]. It is often employed together with cholesterol which acts a membrane stabiliser. 
DPPC is found abundantly in eggs and is a prominent lipid found in cell membrane and in lung 
surfactant. The DPPC used for this work was however synthetically produced with a purity  
≥ 99 %. The lipid was dissolved in 2:1 (v/v) chloroform: methanol mixture at a concentration 
of 10 mg/mL and stored in glass vials at -20 °C.  
 
 
 
DPPC 
 
2.2.1.2 DOPE 
Dioleoylphosphoethanolamine is a conical unsaturated non-bilayer synthetic phospholipid. 
DOPE forms an inverted hexagonal phase due to its negative spontaneous curvature [116]. It is 
often employed as a co-lipid or a helper lipid in liposome formulation. DOPE is a neutral lipid 
with a molecular weight of 744.034 g/mol and a Tm of -16 °C and known to enhance the fusion 
of liposomes with endosomes facilitating incorporation into the cellular membrane [117].  The 
DOPE used for this work was of a purity ≥ 99 %. Aliquots of 10 mg/mL of the lipid were 
dissolved in 2:1 (v/v) chloroform: methanol mixture and stored in glass vials at -20 °C. 
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DOPE 
 
2.2.1.3 DOTAP 
Dioleoyltrimethylammoniumpropane is a synthetic unsaturated cationic lipid with a molecular 
weight of 698.542 g/mol and a Tm of < 5 °C. It is widely regarded as a standard for lipofection 
i.e. liposomal transfection. A DOTAP of ≥ 99 % purity was used for this work. The lipid was 
dissolved in 2:1 (v/v) chloroform: methanol mixture at a concentration of 10 mg/mL and stored 
in glass vials at -20 °C.  
 
 
DOTAP 
 
2.2.1.4 Cholesterol 
Cholesterol is a lipophilic molecule with a single polar hydroxyl group. It has a molecular 
weight of 386.65 g/mol. Cholesterol stabilises bio-membranes and liposomes by imparting 
mechanical strength and flexibility. Furthermore, it improves phosphatidylcholine vesicle 
resistance and prevents vesicle aggregation [118]. Cholesterol in liposomal formulations is also 
known to increase the transfection efficiency [119]. Cholesterol was dissolved in 2:1 (v/v) 
chloroform: methanol mixture at a concentration of 10 mg/mL and stored in glass vials at  
-20 °C.  
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Cholesterol 
 
 
2.1.2 Polymers 
2.1.2.1 Branched Polyethylenimine 
Polyethylenimine (PEI) is a polymer obtained by the polymerisation of aziridine. bPEI consists 
of repeating units composed of an amine group and two carbon aliphatic CH2-CH2 spacer [120]. 
It is an organic macromolecule with a high cationic charge-density potential. Every third atom 
in bPEI is an amine which can be protonated. Due to the close neighbourhood of the many 
linker amino groups, PEI retains a substantial buffering capacity at virtually any pH [121]. bPEI 
has been used successfully for delivering plasmids both in vitro and in vivo [56]. For this work, 
bPEI with a molecular weight of 25 kDa was used. 100 mg of the polymer was added to a 
beaker glass containing 80 mL of milliQ® water. pH was adjusted to 2.0 using 6M HCl. The 
solution was stirred for 4 h at 500 rpm on a magnetic stirrer at RT. Finally, the pH was adjusted 
to 7.0 using 6 M NaOH and the volume was made up to 100 mL using milliQ® water. The 
solution was filter sterilised using 0.2 µm syringe filter (Whatman). Aliquots of 1mg/mL were 
stored at -20 °C until further use.  
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Branched PEI 
 
 
2.1.2.2 Linear Polyethylenimine 
Linear PEI is a linear variant of PEI containing only secondary amines. The lPEI used in this 
work is a commercially available fully deacylated variant. Deacylation of PEI is reported to 
increase the transfection efficiency [77]. lPEI contains larger neighbouring ethylenimine 
segments resulting in 11 % increase in the amount of protonable nitrogen. A hydrochloride salt 
form of lPEI, PEI MAX 40 kDa was used for this work. 50 mg of the powder was dissolved in 
a beaker containing 40 mL of milliQ® water. The solution was stirred on a magnetic stirrer and 
was neutralised to a pH of 7.0 with 6 M NaOH to obtain a 22 kDa linear polyethylenimine. The 
solution was made up to 50 mL with milliQ® water and filter sterilised using 0.2 µm syringe 
filter (Whatman). Aliquots of 1 mg/mL were stored at -20 °C.  
 
 
 
Linear PEI 
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2.1.3 Curcumin 
Curcumin (1,7-bis(4-hydroxy-3-methoxyphenyl)-1,6-heptadiene-3,5-dione) is a naturally 
occurring phenolic compound obtained from the alcoholic extracts of Curcuma longa. The 
rhizome of this plant, turmeric, has been extensively used for its culinary and anti-bacterial 
properties. Being excitable with light at 420 nm, is extensively used as a photosensitiser for 
photodynamic therapy. In this work, curcumin loaded liposomes have been used for photo-
chemical internalisation studies.  
 
2.1.4 Nucleic acids 
2.1.4.1 HT-DNA 
For the experimental practice purposes, herring testes DNA (HT-DNA) was used. 625 mg of 
HT-DNA (1500 bp) was added to a beaker containing 125 mL milliQ® water. The DNA 
solution was left to swell for 1 h followed by overnight stirring on a magnetic stirrer at RT. 
DNA samples were analysed by gel electrophoresis and quantified spectrophotometrically 
(Ultrospec 3000, Pharmacia Biotech) by determination of OD260/280 ratio. The solution was filter 
sterilised through 0.2 µm syringe filters (Whatman) and stored in 5 mg/mL aliquots at -20 °C.  
 
2.1.4.2 pCMV-luc 
pCMV-luc is a plasmid DNA 6233 bp is size. It encodes for firefly luciferase under 
cytomegalovirus (CMV) promoter. It is used frequently for reporter gene assays to quantify the 
gene expression. In the present work, pCMV-luc was extensively used to determine transfection 
efficiencies of various delivery vehicles. pCMV-luc was transformed using JM109 competent 
Escherichia Coli (E. Coli). The plasmid confers ampicillin resistance to the transformed 
bacteria.  SOC broth was prepared by dissolving 27 g of the nutrient mixture in 1 L of milliQ® 
water. In case of SOC agar plates, 15 g of agar was added to the above. The mixture was 
autoclaved and left in a water bath at 60 °C. 100 mg ampicillin was added to make a final 
concentration of 100 µg/mL. SOC agar was pipetted onto sterile Petri dishes and let to settle. 
E. Coli was thawed on ice and re-suspended into a culture tube (Pyrex®; 16x125 mm) 
containing SOC broth and incubated for 1 h in a shaking incubator (IKA KS4000 IC) at 37 °C. 
20 µL of bacterial suspension was added to 20 µL 10 mM Tris buffer (pH 8.0) containing 1 µg 
plasmid DNA. The mixture was transferred into electroporation cuvettes (Bio-Rad, 0.2 cm) 
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placed on ice. The cuvette was pulsed (Bio-Rad Gene Pulser™) once at 2.5 kV (capacitance 25 
µF, resistance 200 Ω) [122]. The mixture was immediately transferred into SOC medium 
containing culture tubes and incubated for 1 h on a shaking incubator (IKA KS4000 IC). 
Bacteria were inoculated onto selective SOC agar plates and incubated overnight at 37 °C. A 
single colony of E. Coli was selected and transferred into an Erlenmeyer flask containing 1 L 
of SOC broth and incubated at 37 °C in a shaking incubator. Plasmid DNA from the resulting 
bacteria was isolated using QIAfilter Plasmid Giga Kit (Qiagen). Plasmid DNA was analysed 
by agarose gel electrophoresis using a DNA ladder as a control. Quantification was performed 
by determining the OD260/280 ratio (Ultrospec 3000). pCMV-luc was filter sterilised and 1 
mg/mL aliquots were stored at -20 °C.  
 
2.1.4.3 pEGFP-N1 
Plasmid DNA pEGFP-N1 of 4700 bp expressing green fluorescence protein was used for 
visualisation of gene expression in this work. pEGFP-N1 was transformed and isolated in the 
same manner as pCMV-luc (section pCMV-luc) with the only difference being the selective 
antibiotic i.e. kanamycin. Samples were filter sterilised and stored in 1 mg/mL aliquots at  
-20 °C. 
 
2.1.4.4 siRNA 
Different kinds of siRNAs were used for this work depending upon the gene intended to be 
downregulated. Anti-luc siRNA 1 directed against firefly luciferase (siLuc, 5´-
GAUUAUGUCCGGUUAUGUA-3´) and luciferase GL3 duplex siRNA directed against GL3 
luciferase (siGL3, 5´-GCCAUUCUAUCCUCUAGAGGAUG-3´) were used for targeting the 
luc gene. For downregulation of SELE gene, SELE siRNA duplex directed against E-selectin 
(siSELE) and three unique dsiRNA 27mer duplexes targeted against E-selectin (Trilencer) were 
employed. As negative control for the knockdown experiments, a non-targeting, non-specific 
siRNA designed to have no silencing effects on rat, mouse and human genes, siRNA No. 2 
(siCtrl) and Trilencer-27 universal scrambled negative control siRNA duplex was used. 
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2.1.5 Cell lines  
For in vitro transfection, knockdown and toxicity experiments, different cell lines were used 
depending upon the experiment. For transfection and knockdown experiments, SK-OV-3 
human epithelial ovarian adenocarcinoma cells, A549 human epithelial lung cancer cells, HeLa 
human epithelial cervical cancer cells, lentiviral transformed HeLa luc+GFP cells co-
expressing firefly luciferase and GFP under CMV promoter, transformed SK-OV-3-luc cells 
expressing GL3 luciferase, PCS-100-012™ primary human coronary artery endothelial cells 
and EA.hy926 human endothelial hybrid cells obtained by fusion of primary human umbilical 
vein cells (HUVEC) with thioguanine resistant A549 by exposure to polyethylene glycol were 
used [123]. For toxicity studies a sensitive mouse fibroblast cell line, L929, considered as a 
standard for toxicity testing, was used [124-126].  
 
2.1.6 Chorioallantoic membrane 
For the in vivo studies, a well-established chorioallantoic membrane (CAM) model was used 
[127-129]. For this purpose, specific pathogen free fertilised chicken eggs each weighing 50-
60 g were used. 
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2.2 Experiments 
2.2.1 Formulation 
2.2.1.1 Preparation of liposomes 
Depending upon the lipids used in liposomal formulation, appropriate amounts of lipids 
dissolved in 2:1 (v/v) chloroform: methanol mixture were added to a 5 mL round bottom flask 
containing 2 mL of 2:1 (v/v) chloroform: methanol to facilitate homogenous mixing. Using a 
rotary evaporator (Laborota 4000) equipped with a vacuum pump, the lipids were evaporated 
at 40 ºC to obtain a thin film. The lipid cake was freeze dried (Christ Beta I) overnight to remove 
any remaining solvent. The lipid film was rehydrated using 20 mM HEPES buffer (pH 7.4) and 
sonicated in a bath sonicator to obtain a uniform suspension of liposomes. The liposomes were 
then extruded 21 - 23 times through 400 and 200 nm polycarbonate membranes (Whatman) 
using an extruder (Avanti Mini Extruder) to reduce their size. Liposomes were filtered through 
0.2 µm syringe filters prior to use.  
 
Similar procedure was followed for curcumin loaded liposomes with the exception that 
curcumin dissolved in 2:1 (v/v) chloroform: methanol was added to the lipids in the round 
bottom flask at a ratio of 1:300 (curcumin: lipid) 
 
2.2.1.2 PEI-Au conjugation 
For structural elucidation, PEI was labelled with gold nanoparticles. For this purpose, branched 
PEI (25 kDa) was pre-activated with Traut’s reagent (2-iminothiolane hydrochloride; Sigma 
Aldrich) in a similar method described previously with slight modifications [130]. Briefly,  
0.2 mM iminothiolane was added dropwise to 22 mM PEI (dissolved in PBS; pH 7.4) under 
constant stirring at room temperature for 24 h. The reaction was stopped by addition of 0.1M 
NaOH. Unreacted Traut’s reagent was removed using a centrifugal concentrator (Vivaspin 6, 
cut-off 10 kDa). The mixture was centrifuged (Beckman) at 3000 x g for 15 min. The 
supernatant thiolated PEI was then freeze dried (Christ Beta I) overnight. The lyophilised 
product was weighed and reconstituted to 1 mg/mL with milliQ® water. The introduced thiol 
groups were then used for binding the gold nanoparticles (10-20 nm diameter in citrate buffer).  
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2.2.1.3 Polyplex preparation 
Polyplexes (PP) were prepared according to their charge ratio (N/P ratio) which is the ratio of 
nitrogen atoms in PEI to phosphate atoms in nucleic acids. N/P ratios ranging from 2 to 30 were 
used for preparing the polyplexes. For the formation of polyplexes, either branched or linear 
PEI was used. PEI diluted in 10 mM HEPES (pH 7.4) was pipetted into micro reagent tubes 
containing either HT-DNA or pDNA diluted in 10 mM HEPES (pH 7.4) or siRNA diluted in 
1x siRNA dilution buffer and incubated for 25 min under a laminar airflow hood at RT. To 
facilitate homogenous mixing, equal volumes of PEI and DNA/siRNA solutions were used.  
 
2.2.1.4 Formation of lipopolyplexes  
For the formation of lipopolyplexes (LPP), appropriate amounts of liposomes depending upon 
liposome to PEI mass ratio were diluted in 10 mM HEPES. Equal volume of the diluted 
liposomal solution and polyplexes were triturated vigorously in a micro reagent tube and 
incubated for different time periods ranging from 1 h to 4 h under a laminar airflow hood at RT. 
 
2.2.2 Physicochemical characterisation  
2.2.2.1 Dynamic light scattering 
The diameter of the liposomes, polyplexes and lipopolyplexes was analysed by dynamic light 
scattering (DLS) using a Zetasizer Nano ZS (Malvern Instruments) in a clear disposable folded 
capillary cell (DTS1060; Malvern Instruments). Prior to measurement, liposomes were diluted 
1:100; polyplexes and lipopolyplexes were diluted to a ratio of 1:20 with 10 mM HEPES (pH 
7.4). For analysis of the data, viscosity (0.88 mPa.s) and refractive index (1.33) of water at  
25 ºC were considered. The instrument is equipped with a 10 mW HeNe laser. Measurements 
were performed at a wavelength of 633 nm and a detection angle of 173º backscatter. 
Measurement position and laser attenuation were automatically adjusted by the instrument 
depending upon the sample. The instrument performs 15 size runs per measurement with each 
lasting 10 s. Three independent formulations were measured and the mean of the measurements 
is reported. 
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2.2.2.2 Laser Doppler velocimetry 
The zeta potential measurements were performed by laser Doppler velocimetry (LDV) using 
the Zetasizer Nano ZS in a clear disposable folded capillary cell (DTS1060; Malvern 
Instruments). The complexes (polyplexes and lipopolyplexes) were diluted as described in 
section 2.2.2.1. Depending upon the sample, the instrument automatically performs 15-100 runs 
per measurement. Three independent formulations were measured and the mean of the 
measurements is reported.  
 
2.2.2.3 Storage stability 
For evaluating the storage stability, lipopolyplexes with lPEI (N/P 9.5) were prepared as 
described in sectionFormation of lipopolyplexes. The lipopolyplexes were then stored at 4 °C 
for 1, 3, 7, 14, 21 and 30-day time periods and evaluated using dynamic light scattering and 
laser Doppler velocimetry. The effect of extended storage periods on transfection was evaluated 
at similar time intervals. 
 
2.2.3 Complex stability studies 
2.2.3.1 Gel retardation assay 
Polyplexes and lipopolyplexes were subjected to gel electrophoresis to evaluate their integrities. 
Both polyplexes and lipopolyplexes containing 0.4 µg of pDNA were prepared as described in 
the sections 2.2.1.3 and 2.2.1.4 respectively. 0.4 µg unbound pDNA and milliQ® water were 
used as positive and negative controls respectively. The samples were loaded together with 1x 
loading buffer onto 1 % agarose gel containing ethidium bromide and electrophoresis was 
carried out in 1x TBE buffer (pH 8.3) on a Thermo Hybaid Electro 4 gel electrophoresis 
chamber equipped with LKB 2197 constant power supply unit set at 80 V for 1 h. The gels were 
then analysed at a wavelength of 312 nm under trans-illuminator (BioDoc Analyse Ti5). 
 
2.2.3.2 Heparin assay 
The stability of the complexes was analysed in presence of a naturally occurring polyanion in 
biological systems, heparin. For this assay, polyplexes and lipopolyplexes were prepared with 
1 µg pDNA (as described in the sections 2.2.1.3 and 2.2.1.4 respectively) and incubated 
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together with decreasing concentrations (30, 20, 15, 10, 5, 1 IU) of heparin. After 30 min of 
incubation in heparin, the samples were packed together with 1x loading buffer on 1 % agarose 
gel containing ethidium bromide and electrophoresis was carried out (Thermo Hybaid Electro 
4) in 1x TBE buffer at 80 V for 1 h (LKB 2197 power supply). The gels were analysed under a 
trans-illuminator (BioDoc Analyse Ti5) at 312 nm. 
 
2.2.3.3 Ethidium bromide intercalation assay 
Polyplexes and lipopolyplexes containing 0.5 µg pDNA were prepared as described in the 
sections 2.2.1.3 and 2.2.1.4 respectively. 50 µL of the complexes were added to a white opaque 
bottom 96-well plate (Brand). To these, 50 µL of ethidium bromide (0.4 µg/mL) was added and 
incubated in dark for a further 30 min at 200 rpm in an orbital shaker (IKA KS4000 IC). As 
controls, pDNA, ethidium bromide and milliQ® water were used. The fluorescence was 
measured (FLUOstar® Optima) with an excitation wavelength of 280 nm and emission 
wavelength of 610 nm [131]. 
 
2.2.4 Structural, morphological and surface characterisation  
2.2.4.1 Scanning electron microscopy 
Scanning electron microscopy (SEM) was performed using a Hitachi S-510 scanning electron 
microscope. Polyplexes with an N/P ratio of 9.5 containing 3 µg pDNA were briefly incubated 
for 25 min. After this incubation time, they were added to an equal volume of liposomes diluted 
with 10 mM HEPES (pH 7.4) and further incubated for a period of 45 min. 10 µL of the 
lipopolyplexes was pipetted onto specimen stubs with conductive carbon tabs (PLANO Leit-
Tabs; Ø 9 mm) and left to dry under a laminar airflow hood. 10 - 15 µL of 2 % glutaraldehyde 
was pipetted onto the sample in such a manner that it covered the entire sample and incubated 
for 40 min. Samples were immersed thrice in milliQ® water and then fixed using 10 - 15 µL 2 
% osmium tetroxide for 1 h. The samples were immersed again thrice in milliQ® water, and 
then dehydrated using ascending concentrations (10, 25, 50, 75, and 95 %) of ethanol ending 
with absolute ethanol with each step lasting 5 min. The samples were then completely 
dehydrated by supercritical drying (Bal-Tec CPD 030 Critical Point Dryer) using liquid CO2 as 
transition liquid. The samples were immediately sputtered (Edwards S150 Sputter Coater) with 
gold at 1.3 x 10-4 bar vacuum and 10 mA current. The samples were examined (WD  
15 - 17.5 mm) at an accelerating voltage of 5 kV and 30 µA emission current under 4 x 10-7 bar 
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vacuum. The microscope was retrofitted with a digital image acquisition system (DISS 5) and 
the micrographs were recorded digitally.  
 
2.2.4.2 Cryo-field emission scanning electron microscopy 
Cryo-SEM was performed using a field emission scanning electron microscope JSM-7500F 
equipped with a lanthanum hexaboride (LaB6) cathode. Freeze fracture technique was utilised 
for analysing the samples [132]. Liposomes and lipopolyplexes (lPEI; N/P 9.5) prepared as 
described in the sections 2.2.1.1 and 2.2.1.4 respectively were pipetted into specimen rivets and 
shock froze in a slush chamber containing liquid nitrogen. Samples were transferred into a 
liquid nitrogen cryo transfer system (Alto 2500). The upper half of the rivet was knocked off 
with an integrated cold knife to create a fracture. Samples were sublimated at -95 °C and 
sputtered with platinum at -140 °C. The samples were then transferred into the specimen 
chamber maintained at -140 °C and observed between 2 - 5 kV accelerating voltages and an 
emission current of 10 µA.  
 
2.2.4.3 Transmission electron microscopy 
Structural investigation of the lipopolyplexes was performed using a JEM-3010 ultra-high 
resolution transmission electron microscope (TEM) equipped with a retractable high-resolution 
slow scan CCD-Camera (Gatan MegaScan 794). Complexes (lPEI, N/P 9.5) prepared as 
described in the sections 2.2.1.3 and 2.2.1.4 were diluted to 1:10 ratio with 10 mM HEPES 
buffer (pH 7.4) and mounted onto 300 mesh carbon coated copper grids which were glow 
discharged (Edwards S150B) for 1 min to render them hydrophilic. After 15 min, the grid was 
bought in contact with a drop of milliQ® water thrice to remove the residual buffer. A drop of 
2 % uranyl acetate solution was placed onto the grid to negatively stain the sample for 5 min. 
The sample was examined at an accelerating voltage of 300 kV and 110 µA emission current 
with current densities between 50-60 pA/cm2.  
 
2.2.4.4 Atomic force microscopy 
AFM was used to determine the morphology of the particles and to confirm the particle size. 
10 µL of lipopolyplexes prepared as described in the section 2.2.1.4 were pipetted onto silica 
wafers which were glued to glass slides. The samples were washed gently with milliQ® water 
to remove excess of buffer and allowed to dry before being flushed with a stream of compressed 
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air. Surface analysis was performed under ambient conditions using a Nanowizard® 1 AFM 
with an aluminium coated pyramidal silicon nitride probe (HQ:NSC16/Al BS) having a 170 
kHz resonance frequency and a force constant of 40 N/m. Images were acquired with constant 
amplitude attenuation at scan rates between 0.5 to 1 Hz. The raw images were processed using 
JPKSPM data processing software. 
 
2.2.5 Cell culture studies 
2.2.5.1 Maintenance of cells 
SK-OV-3 and SK-OV-3 luc, cell lines were cultivated at 37 ºC and 7 % CO2 under humid 
conditions in IMDM medium (Biochrom) supplemented with 10 % foetal bovine serum (PAA 
Laboratories). HeLa, HeLa luc+GFP, A549, EA.hy926 were maintained at 37 ºC and 8.5 % 
CO2 under humid conditions in DMEM-High Glucose medium (Biochrom) supplemented with 
10 % foetal bovine serum (PAA Laboratories). L929 cells were maintained at 37 ºC and 8.5 % 
CO2 under humid conditions in DMEM-Low Glucose medium (Biochrom) supplemented with 
10 % foetal bovine serum (PAA Laboratories) PCS-100-012™ cells were grown in MCDB 153 
medium (Biochrom) supplemented with endothelial cell growth kit VEGF (PCS-100-041™) 
constituting to 5 ng/mL rh VEGF, 5 ng/mL rh EGF, 5 ng/mL rh FGF basic, 15 ng/mL rh IGF-
1, 10 mM L-glutamine, 0.75 Units/mL heparin sulphate, 1 µg/mL hydrocortisone, 50 µg/mL 
ascorbic acid, 2 % foetal bovine serum in final medium. PCS-100-012™ cells were maintained 
at 5 % CO2 at 37 °C. All cells were maintained under humid conditions. Cells were grown as 
monolayers in  100 mm tissue culture grade Petri dishes and passaged upon reaching 80 % 
confluency.    
 
2.2.5.2 Transfection experiments 
For transfection and knockdown experiments, the cells were seeded onto 96-well microtiter 
plates (CytoOne®) with a density of 10,000 cells per well and incubated for 24 h before 
transfection. The complexes were prepared as described in sections 2.2.1.3 and 2.2.1.4 in a 
manner such that the concentration of pCMV-luc per well would be 0.2 µg. Medium from the 
microtiter plates was aspirated and 75 µL of fresh serum containing medium was added. 25 µL 
of complexes were added in quadruplicates to the wells and the plates were gently swirled. 
Medium was either changed or fresh medium containing serum was added additionally to the 
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wells after 4 h depending upon the experiment. The cells were left in the incubator for 48 h 
before they were further assayed. All the transfection experiments were performed thrice and 
the results are mean values of the luciferase expression normalised in regard to the protein 
concentration. 
 
2.2.5.3 RNAi experiments 
RNAi experiments were performed similar to transfection experiments (section 2.2.5.2) with 
the difference that the complexes were prepared with siRNA to give a final concentration of 7.2 
pmol per well. RNAse free water and buffers have been used for RNAi experiments. All RNAi 
experiments have been performed thrice and the knockdown is expressed as percentage of siCtrl 
control siRNA. 
 
2.2.5.4 Photo-chemical internalisation 
Enhancement of the transfection via photo-chemical internalisation was performed using a 
custom-made prototype Generation I LED irradiator (Lumundus GmbH) with an array of LED 
lights designed to irradiate a 96-well microtiter plate was used (Figure 6). The LED irradiator 
was equipped with LED’s capable of emitting light at 457 and 620 nm wavelengths with an 
option to vary time and current intensity (which together correspond to radiation intensity). 
Transfection experiments were performed as described in section 2.2.5.2 using curcumin loaded 
lipopolyplexes (lPEI; N/P 9.5) containing 0.2 µg pCMV-luc prepared as described in section 
2.2.1.4. 4 h after the transfection, cells were irradiated at 457 nm at various radiation intensities 
and additional medium was added to the cells and incubated for a further 48 h. Luciferase 
activity was determined using luciferase assay.  
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Figure 6: Prototype LED irradiation device; clockwise: control unit, bottom side of the 
irradiating head with LEDs and top view of the irradiating head during irradiation [133]  
 
2.2.5.5 Ultrasound enhanced release 
The use of ultrasound to enhance the release of the delivery vehicles was performed using an 
eZono 3000 portable medical ultrasound device. SK-OV-3 and PCS-100-012™ cells were 
seeded onto a  60 mm Petri dish at a seeding density of 100,000 cells per dish. Transfection 
experiments were performed as described in section 2.2.5.2 using complexes (with lPEI; N/P 
9.5) containing 1 µg pCMV-luc prepared as described in sections 2.2.1.3 and 2.2.1.4 . 1 and 4 
h post transfection, the petri dishes were placed on a rotatable petri dish holder and the cells 
were treated with ultrasound at a frequency of 15 Mhz with a penetration depth of 1.1 cm and 
a mechanical index (MI) of 1.5 while being rotated on the petri dish holder (Figure 7: 
Ultrasound enhanced gene transfer).  
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Figure 7: Ultrasound enhanced gene transfer; setup showing the portable ultrasound device 
with the transducer placed in petri dish 
 
2.2.5.6 Pathway analysis 
To determine the exact mechanism of cellular uptake, pathway analysis was carried out. 
Chlorpromazine, Dynasore, Filipin III were used as pathway inhibitors. SK-OV-3 and HeLa 
luc+GFP cells were seeded at a cell density of 10,000 cells per well and incubated overnight. 
On the following day, medium was aspirated and the cells were washed with PBS containing 
Ca+ and Mg+ (pH 7.4) to remove any serum residues which can inactivate the effect on the 
inhibitors. Fresh medium without serum containing the either 80 µM Dynasore, 5 µM of 
chlorpromazine or 3 µM Filipin III was pipetted into the wells and incubated for 30 min. The 
cells washed with PBS containing Ca+ and Mg+ (pH 7.4) and the complexes (with lPEI; N/P 
9.5) prepared as described in 2.2.1.3 and 2.2.1.4 containing either 0.2 µg pCMV-luc or 7.2 pmol 
siRNA were added to the wells and the luciferase activity was determined after 48 h. 
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2.2.5.7 Luciferase assay and protein quantification 
Luciferase expression was determined 48 h post transfections. The cells were washed twice 
with PBS containing Ca+ and Mg+ (pH 7.4) and 50 µL of 1x cell culture lysis reagent (Promega) 
was added to each well. Cells were incubated in a shaking incubator (IKA KS4000 IC) at 200 
rpm for 30 min. 20 µL of the lysate was added to a white 96-well opaque plate (Brand). The 
plate was measured in a luminometer (FLUOstar® Optima) equipped with a pump used for 
injecting the luciferase assay mixture. Aliquots of luciferase assay reagent and the beetle 
luciferin were freshly thawed, mixed and primed into the pump. A protocol was created with a 
10 s integration time for luminescence detection. The instrument automatically pumped the 
luciferase assay mixture into each well and measured before proceeding to the next. The results 
are expressed in relative luminescence units (RLU). 
 
Protein quantification was performed using the Pierce protein BCA assay kit [134]. 25 µL of 
the cell lysate from the lysis step (section 2.2.5.7) was added to a transparent 96-well microtiter 
plate for protein quantification. 25 µL of serial dilutions of standard bovine serum albumin 
(2000 µg/mL - 25 µg/mL) were added to the microtiter plate. 200 µL of the working reagent 
containing bicinchoninic acid was added to each well and the plate was incubated in a shaking 
incubator (IKA KS4000 IC) at 200 rpm for 30 min at 37 °C. The plate was let at RT for 15 min 
and the protein quantification was performed by measuring the absorbance at 570 nm using a 
plate reader (Tecan Spectra III). The protein values were used to normalise the luciferase 
expression and the final values were expressed in RLU / mg protein. 
 
2.2.5.8 E-selectin ELISA 
ELISA was performed to determine the knockdown of E-selectin expression in endothelial 
EA.hy926 cells. To enable expression of endothelial leukocyte adhesion molecule 1; E-selectin, 
100 µL of medium containing 350 U/mL Tumour Necrosis Factor-α (TNF-α) was added to each 
well and the cells were incubated to 4 h [135]. Knockdown was performed (with complexes 
containing lPEI; N/P 9.5) as described in 2.2.5.3 using 16 pmol SELE siRNA or 25 pmol 
Trilencer dsiRNA 27mer pools (per well) with Trilencer scrambler siRNA and siCtrl as 
controls. Prior to use, dsiRNA was diluted with 1x siRNA dilution buffer and heated to 94 °C 
for 2 min to enable duplex formation. After 48 h, the supernatant from each well was collected. 
A 96-well plate was coated with 50 µl of 10 µg/mL anti-human E-selectin monoclonal antibody 
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diluted in PBS (pH 7.4) and incubated for 16 h at 4 °C. Plates were washed twice with 300 µL 
PBS (pH 7.4) to remove unbound antibodies and tapped on a paper towel. Plates were blocked 
with 1 % BSA containing PBS buffer (pH 7.4), sealed with adhesive plate seals and incubated 
for 2 h at RT. 20 µl of supernatant from the cells was added to the corresponding wells of the 
antibody coated plate containing 80 µl PBS (pH 7.4). 100 µL of human E-selectin standard 
diluted with PBS (pH 7.4) was added to the wells in serial dilutions (50 ng/ml - 0.4 ng/mL) as 
a standard reference. As a negative control, 100 µL PBS buffer (pH 7.4) was used. 50 µL of 10 
µg/mL HRP conjugated anti-human E-selectin monoclonal antibody was added to each well. 
Plates were sealed with an adhesive plate seal and incubated for 2 h at RT in a shaking incubator 
(IKA KS4000 IC) at 100 rpm. Following incubation, plate was washed four times with PBS 
(pH 7.4). 100 µL of 3,3’,5,5’-Tetramethylbenzidine substrate solution was added to the wells 
and incubated for 10 min at RT in a shaking incubator (IKA KS4000 IC) at 100 rpm. 100 µL 
of 0.16 M sulphuric acid was added to each well and the absorbance was read immediately at 
450 nm in a plate reader (FLUOstar™ Optima). The E-selectin expression was compared 
against the standard and the results are expressed as ng E-selectin expression. 
 
2.2.5.9 Transfection visualisation 
To qualitatively visualise the transfections, confocal laser scanning microscopy was employed. 
SK-OV-3 cells were seeded at a seeding density of 90,000 cells per well onto 12-well plates 
(Nunclon Delta) containing  15 mm cover slips. The plates were incubated for 24 h before 
being used for transfection. Complexes prepared (with lPEI; N/P 9.5) as described in 2.2.1.3 
and 2.2.1.4 containing 1.75 µg of pEGFP-N1 were added drop wise to each well containing 400 
µL medium containing serum; the plates were gently swirled and incubated. After 4 h, 500 µL 
of medium containing serum was added to the wells and incubated for a further 48 h. The cells 
were then washed twice with PBS containing Ca+ and Mg+ (pH 7.4) and fixed with 4 % 
formaldehyde solution for 20 min after which the cell nucleus was counterstained with 0.1 
µg/mL DAPI (4',6-diamidino-2-phenylindole) for 20 min. Finally, the cells were washed with 
PBS (pH 7.4) and the cover slips were mounted onto slides with a mounting medium 
(FluorSave™) and sealed using a transparent nail polish.  
 
The cells were examined under a Confocal Laser Scanning Microscope (Zeiss Axiovert 
100M/LSM 510). A class 4 argon ion laser (Coherent Enterprise II) laser with 364 and 488 nm 
excitation wavelengths for observing nuclear counterstaining and GFP expression respectively 
 38 
 
was used. Detector equipped with band pass filters of 505-530 nm for GFP and 385-470 nm for 
DAPI was used for recording the micrographs. Similar detector gain (master gain) and pinhole 
size was used across all the samples.  
 
2.2.6 Cytotoxicity studies 
2.1.6.1 MTT assay 
Cytotoxicity of the complexes was determined by MTT assay using thiazolyl blue tetrazolium 
bromide. A cell density of 10,000 L929 cells per well were seeded onto 96-well plates. pCMV-
luc containing complexes were prepared in a similar manner like in transfection experiments 
(section 2.2.5.2) and pipetted into the wells. As a positive control 0.1 % Triton™ X-100 was 
used and untreated cells were used as negative control (Blank). The plates were gently swirled 
and incubated. After 4 h, additional medium was added to the wells and incubated for another 
48 h. After the incubation time, the plates were washed twice with PBS containing Ca+ and Mg+ 
and then medium containing MTT assay reagent was added to each of the 96 wells. The cells 
were incubated for another 4 h during which the viable cells metabolize the MTT dye and 
reduce it to formazan crystals [136]. The remaining medium was aspirated and 200 µL of 
dimethyl sulphoxide was added to each well to dissolve the formazan crystals. Absorbance was 
measured using FLUOstar™ Optima plate reader at 570 nm.  
 
2.1.6.2 LDH Assay 
Cellular toxicity as a function of membrane integrity was determined by lactate dehydrogenase 
assay (LDH) in L929 cells. A density of 10,000 cells per well were seeded onto 96-well plates 
and incubated overnight. The medium was changed and complexes containing pCMV-luc were 
prepared in a similar manner to the transfection experiments (section 2.2.5.2) and pipetted 
dropwise into the wells. As a positive control 0.1% Triton™ X-100 was used. Untreated cells 
were used as negative control (Blank) and wells with only medium were used as a background 
control. The plates were gently swirled and incubated. After 4 h additional medium to the wells 
and incubated for another 48 h. After incubation time, 100 µL of medium from the assay plates 
was transferred onto corresponding wells of a clear 96-well microtiter plate. 100 µL of freshly 
prepared reaction mixture (LDH kit, Roche) was added to the plate and incubated for 30 min 
after which the absorbance was determined at 485 nm using a FLUOstar™ Optima plate reader.  
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2.2.7 Haemocompatibility studies 
2.1.7.1 Haemolysis assay 
To determine the haemolytic potential of the complexes on blood, erythrocytes isolated from 
fresh human blood were used [137]. Fresh blood was drawn into tubes containing 3.8 % sodium 
citrate (9:1) followed by centrifugation at 500 x g for 20 min. The obtained red blood cell pellet 
was washed thrice with PBS buffer (pH 7.4) and diluted to 1:50 with PBS (pH 7.4). Complexes 
(with lPEI and bPEI; N/P 9.5 and 15 respectively) containing to 1 µg pCMV-luc were prepared 
as described in sections 2.2.1.3 and 2.2.1.4. The samples were diluted 1:1 with erythrocytes to 
reach a final volume of 200 µL [138]. Samples were incubated for 1 h in at 150 rpm in a shaking 
incubator (IKA KS4000 IC) at 37 ºC. The samples were subsequently centrifuged and the 
absorbance of the collected supernatant was determined at 540 nm in a FLUOstar® Optima 
plate reader. PBS buffer (pH 7.4) and 0.1 % Triton™ X-100 were used as controls and the 
absorbance values of Triton™ X-100 were considered as 100 % haemolysis. 
 
2.1.7.2 Activated partial thromboplastin time test 
Activated partial thromboplastin time (aPTT) test was used to determine the effect of the 
complexes on coagulation.  Fresh blood was drawn into tubes containing 3.8 % sodium citrate 
(9:1) followed by centrifugation at 1500 x g for 10 min to separate the plasma fraction. Normal 
aPTT values of plasma were checked and the plasma was stored at -80 °C until further use. The 
aPTT test was performed in a coagulation analyser (Coatron M1) using the TEClot aPTT-S Kit 
as per the manufacturer’s protocol with slight modifications. 25 µL of plasma was mixed with 
25 µL of complexes (with lPEI and bPEI; N/P 9.5 and 15 respectively) prepared as described 
in sections 2.2.1.3 and 2.2.1.4 containing 1 µg pDNA. 25 µL of prewarmed 0.025 M calcium 
chloride was added to this mixture followed by addition of equal volume of aPTT reagent to 
activate coagulation. Coagulation was confirmed spectrophotometrically and the time was 
recorded in seconds 
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2.2.8 In vivo chorioallantoic membrane model 
Specific pathogen free fertilised chicken eggs were incubated (Ehret KMB 6 hatching 
incubator) at 37 °C in a humidified atmosphere (>60 % RH). The CAM experiments were 
performed according to established protocols with slight modifications [129, 139]. On egg 
development day (EDD) 3, a 3 mm  hole was bored into the basal part of the shell and 
approximately 3 mL of albumin was drawn out of the egg using a syringe to prevent the 
adhesion of the CAM to the apical part of shell. The apical part of the shell was cut open ( 30 
mm) to expose the CAM. The bottom end was sealed using a cellophane tape and the apical 
part using a paraffin film. The eggs were further incubated on a frame designed to hold them 
upright to facilitate the development of CAM. On EDD 11, 100 µL mL of the lipopolyplexes 
(with lPEI; N/P 9.5) prepared as described in section 2.2.1.4 containing 0.8 µg pEGFP-N1 was 
injected into the mesoderm of the CAM using a glass cannula. Eggs were further incubated 
until EDD 12. Images of the microvasculature were acquired using a Stemi 2000-C stereo 
microscope equipped with a Moticam 5 CMOS camera. Approximately 1 cm2 of the CAM was 
cut out and washed once with isotonic NaCl (0.9 %). Depending upon the analysis, the cut out 
was either supercritically dried (Bal-Tec CPD 030) for electron microscopy (Hitachi S-510) or 
mounted onto a slide for confocal fluorescence microscopy (Zeiss Axiovert 100M/LSM 510). 
 
2.2.9 Statistical analysis 
All experiments were performed in triplicates and the values are presented as mean ± standard 
deviation, unless otherwise stated. Two-tailed Student’s t-test was performed to identify 
statistical significance differences. Probability values of p < 0.05 were considered significant. 
Statistical differences are denoted as "*" p < 0.05, "**" p < 0.01, "***" p < 0.001. Results have 
been plotted in graphs using Origin graphing program (OriginLab Corporation, Northampton, 
USA). 
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Part III: Results and discussion 
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3.1 Physicochemical properties 
The most vital criteria for efficient gene delivery are nano-sized, slightly cationic and 
physiologically stable complexes. Size of the complexes suspended in aqueous solutions 
determined by Dynamic light scattering called hydrodynamic diameter due to the fact that the 
complexes are in a hydrated, aspherical state.  To correlate the physiological conditions with 
that of the measurements and to facilitate an ion rich environment for the laser Doppler 
velocimetry, all measurements were performed at physiological pH using 20 mM HEPES 
containing 150 mM NaCl (pH 7.4) as a dilution buffer [140].  
 
3.1.1 Hydrodynamic diameter 
Hydrodynamic diameter of the liposomes and complexes was determined using dynamic light 
scattering (DLS) using the size by intensity function. In agreement with previous studies, the 
hydrodynamic diameter of the polyplexes increased decreased with increasing N/P ratios for 
both branched and linear variants [141, 142]. This effect however diminished after an N/P ratio 
of 27 and 25 for bPEI and lPEI respectively. At higher N/P ratios, the polyplexes formed 
aggregates immediately after complexation. In case of bPEI, the complex size decreased from 
298.7 ± 9.3 nm to 188.3 ± 6.4 nm from N/P ratios 3 to 20. lPEI showed a decrease from 210.5 
± 5.5 nm at N/P ratio 2.5 to 124.9 ± 8.2 nm at an N/P ratio of 22. As previously reported, 
regardless of their sizes, there was no significant difference in the diameter of polyplexes 
formed from pDNA or siRNA [61]. 
 
Two different liposomal formulation containing DOTAP, DPPC and cholesterol (DODC); and 
DOPE, DPPC and cholesterol (DDC) were investigated. Considering its charge related 
cytotoxicity, a maximum of 50 % DOTAP was incorporated into the DODC liposomal 
formulations. To reduce the size of the liposomes and to obtain a homogenous unilamellar 
population, the liposomal formulations were extruded [143]. Since the polyplex formulations 
were in the size range of 150 - 180 nm, extrusion was preformed through 400 and 200 nm 
polycarbonate membranes to obtain liposomes in the corresponding size range. Hence all 
liposomes formulated were in a size range of 150 - 170 nm (formulations involving DODC) to 
160 - 180 nm (formulations involving DDC) and were monodisperse (Polydispersity index 
(PDI) of 0.1). Since DOPE readily takes on its hexagonal phase when used solely conditions 
under physiological, DDC liposomes containing high amount of DOPE (≥ 80 %) were highly 
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unstable and aggregated immediately following vesicle preparation. To avoid this problem 
without compromising on its fusogenic properties, amount of DOPE was kept to a maximum 
of 70 mol % in the DDC formulation [144]. After thorough investigations involving different 
N/P ratio of the polyplexes and the mass ratios of liposomes to polyplexes, a consensus was 
reached regarding the size of the lipopolyplexes. A complex size of 200 nm and less is a size 
prerequisite for endocytosis and efficient cellular uptake [145]. Bearing in mind this number, 
all other formulations exceeding this size range were excluded from further studies.  
Lipopolyplexes formed using DODC liposomes with bPEI and lPEI were in a size range of 180 
- 200 nm and those with DDC liposomes were in a size range of 170 - 210 nm.  
 
3.1.2 Zeta Potential 
The other crucial factor effecting cellular interaction is the zeta potential of the complexes. pH 
and ionic strength are the two main factors influencing the zeta potential. For the success of 
gene delivery, the delivery vehicles need to have a minute positive charge [146, 147].  
 
Liposomal formulations involving DODC showed a positive zeta potential. The zeta potential 
increased with increasing DOTAP molar ratios. On the other hand, liposomal formulations 
involving DDC showed a neutral to negative zeta potential. DOPE molar ratio was the 
determining factor the negative charge of the formulations. Negative charge increased with an 
increase in the amount of DOPE. 
 
In case of polyplexes, both bPEI and lPEI showed an increase in the zeta potential with 
increasing N/P ratios. The branched variant of PEI showed a dramatic increase in the zeta 
potential with increasing the amount of polymer, whereas the linear variant showed only slight 
increase in the zeta potential. Since the cytotoxicity of PEI is attributed to its high cationic 
charge, N/P ratios with zeta potential above + 30 mV were not considered for lipopolyplex 
formation [148].  
 
Complexation of liposomes with nucleic acids, complexes and nanoparticles involves either 
electrostatic interactions, mechanically induced interactions, rearrangement of the lipids or the 
combination of these [42, 149]. Lipopolyplexes formed using DODC liposomes showing the 
highest zeta potential (+ 43.9 mV) whereas their DDC counterparts showed a zeta potential less 
than + 4 mV. Therefore, DDC liposomes having highest negative charge were considered for 
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lipopolyplex formation, due to their ability to shield the positive charge of PEI to an extent. Not 
only PEI, but also liposomes used in the formulation of lipopolyplexes play an important role 
in its physicochemical properties which is in agreement with previous studies [75].  
 
Table 1: Physicochemical properties of liposomes, polyplexes and lipopolyplexes. Size and zeta 
potential are expressed as a mean ± standard deviation of three independent measurements 
(n=3) 
 
3.1.3 Storage stability 
Unlike the polyplexes, lipopolyplexes did not tend to form aggregates upon storage. There was 
no significant increase in the size of the complexes upon storage thereby making them suitable 
for in vivo application where size is an important parameter affecting the bio-distribution and 
uptake of the particles [26]. The storage stability study revealed that the loss in biological 
activity of the DDC-lPEI lipopolyplexes after 30 days (at 4 °C) was minimal at 20 % (Figure 
8). The loss in the biological activity could be attributed to the degradation of plasmid DNA 
upon extended storage at 4 °C. 
 
Formulation                                                         Size (nm) ± SD          Zeta Potential (mV) ± SD       PDI 
Liposomes (mol %) 
 
DOTAP:DOPE:Cholesterol (35:50:15) 
DOPE:DPPC:Cholesterol (70:15:15) 
 
168.4 ± 2.5 
174.7 ± 3.3 
 
+40.9 ± 4.6 
-30.9 ± 2.0 
 
0.11 
0.09 
 
Polyplexes  
 
Branched PEI (N/P 15) 
Linear PEI (N/P 9.5) 
 
180.5 ± 11.6 
         166.2 ± 8.7 
 
+ 27.3 ± 4.4 
+ 19.1 ± 2.7 
 
0.35 
0.24 
 
Lipopolyplexes with lPEI polyplexes 
 
DOTAP:DOPE:Cholesterol (35:50:15) 
DOPE:DPPC:Cholesterol (70:15:15) 
 
181.3 ± 7.5 
201.1 ± 5.9 
 
+ 43.9 ± 2.3 
+ 3.7 ± 2.1 
 
0.23 
0.19 
 
Lipopolyplexes with bPEI polyplexes    
 
DOTAP:DOPE:Cholesterol (35:50:15) 
DOPE:DPPC:Cholesterol (70:15:15) 
 
224.6 ± 15.1 
194.0 ± 17.3 
 
+ 51.5 ± 3.5 
+ 9.5 ± 3.7 
 
0.33 
0.38 
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Figure 8 : Storage stability of the lipopolyplexes (DDC-lPEI; N/P 9.5). x-axis represents the 
storage period in days and y-axes represents size (left) and luciferase expression (right) 
respectively 
 
3.2 Structural and morphological analysis 
Microscopy is a valuable tool in science for the analysis of structures not visible to the naked 
human eye. Different forms of microscopy have proved to be invaluable for the characterisation 
of micro and nano-sized structures. The most common microscopes used for structural analysis 
are optical microscopes. Nanoparticles need to possess certain characteristics to able to be 
viewed under an optical microscope. Due to Abbe’s diffraction limit, optical microscopic 
analysis of nano-sized structures is limited to either birefringent samples (polarising 
microscopy), opaque samples (dark field microscopy) or fluorescent samples (confocal 
microscopy) which all give only a vague representation of the actual structure.  
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3.2.1 Electron microscopy 
Electron microscopy was used to determine the morphology and structure of the formulations. 
Electron microscopy enables analysis of the samples beyond optical microscopic limit with a 
much higher resolution. However, unlike optical microscopy, electron microscopy required 
special sample preparation techniques and a certain amount of experience in handling of the 
chemicals used for sample preparation which are often toxic. Certain level of training, 
appropriate skills and thorough knowledge in fundamental physics in required to visualise and 
analyse the micrographs in electron microscopy. Since each sample preparation technique has 
its own advantages and disadvantages, a combination of different techniques was employed to 
obtain the best possible result. 
 
3.2.1.1 Scanning electron microscopy 
SEM was performed to elucidate the morphological characteristics of the lipopolyplexes. Since 
SEM analysis involves exposure of samples to high voltage electron beams and a high vacuum 
chamber, the samples need to be prepared appropriately. This was enabled by fixation with  
2 % glutaraldehyde solution in PBS which helps retain the structural characteristics of the outer 
lipid membrane. Glutaraldehyde, a slowly penetrating fixative preserves the fine structural 
details of the lipopolyplexes in the high vacuum environment of the SEM. Samples for electron 
microscopy need to possess a certain level of contrast to differentiate them from the 
background. Due to its affinity to polar head groups of the phospholipids and due to its high 
electron scattering rate, osmium tetroxide was used as a staining agent of choice [150]. Samples 
devoid of aqueous media is a basic requirement of electron microscopy under high vacuum. To 
render the sample dry without compromising their structure and to avoid shrinkage, 
supercritical drying was employed. After ethanol dehydration of the samples, the samples were 
subjected to supercritical drying using CO2 as a supercritical fluid to remove residual ethanol 
from the samples. The other requirement for scanning electron microscopy is that the samples 
need to be conductive. To achieve this, samples were sputtered with a fine layer of gold. The 
SEM was equipped with an Everhart-Thornley detector to obtain secondary electron images. 
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Figure 9: a.) SEM micrograph of DDC-lPEI (N/P 9.5) lipopolyplexes. b.) A closer view of a 
single lipopolyplex  
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Since the lipopolyplexes were left to dry on the conductive carbon tabs for scanning electron 
microscopy, lipopolyplexes tend to come closer and form clumps or pseudo-aggregates (Figure 
9. a). The SEM micrograph of a lipopolyplex (Figure 9. b) corresponds to the size measured 
using DLS. A gross approximation of the shape and morphological features could be made from 
the micrographs. The micrograph (Figure 9. a) reveals a defined spherical shape of the 
lipopolyplexes and a lot of small clusters of lipopolyplexes joined together and above each 
other. Due to the presence of an aqueous core, under normal conditions, it is rather difficult to 
image liposomes with a normal SEM, despite cumbersome preparation techniques. The fact 
that the SEM micrographs in this study showing distinct structures could be attributed to the 
presence of a polyplex inside liposomes thereby stabilising the structure.  
 
3.2.1.2 Freeze fracture cryo scanning electron microscopy 
Another exceptional method used in the study of liposomes and liposomal formulations is 
freeze fracture method. This method involves using aqueous solutions of liposomes which are 
rapidly froze to temperatures below 100 K using liquid nitrogen. The sample holder containing 
this frozen liposomal mixture broken (freeze fracture) to reveal the structure within. The images 
obtained from such samples often show the so-called replicas of the structures which have been 
removed during the freeze fracture process. This enables imaging of a three-dimensional 
structures of the samples. Freeze fracture allows imaging of the liposomal formulation in their 
original form without any additional preparation techniques.  
 
Much higher image resolution could be obtained using the field emission scanning electron 
microscopy together with a LaB6 cathode as opposed to the tungsten filament in SEM. The 
LaB6 crystals have a lower work function (2.66 eV) than tungsten (4.7 eV) and therefore readily 
emit electrons offering higher brightness and current densities which reduces the background 
noise. The cryo-SEM was equipped with a proprietary gentle beam technology which 
decelerates the incident electrons. A negatively charged stage bias is employed in gentle beam 
which reduces incident electron penetration of the sample and subsequent charging. This 
offered visualisation of the samples at much lower accelerations voltages without 
compromising the resolution.  
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Figure 10: Cryo-SEM micrographs of a.) lipopolyplexes showing distinct shape of the 
lipopolyplexes and b.) a replica left by the lipopolyplexes  
 50 
 
Platinum was used to sputter the samples for cryo-SEM which offers a smaller grain size and a 
thinner deposition compared to gold. Background noise in the form of grain is significantly 
reduced using platinum as a target material for sputtering the samples which greatly enhances 
the signal to noise ratio. The cryo-SEM micrographs confirmed the spherical structure of the 
lipopolyplexes from the SEM with a much better resolution (Figure 10. a). Since this technique 
did not require drying of the lipopolyplex suspension, the lipopolyplexes did not form clumps. 
This enabled effective imaging of the samples even at higher magnifications. The replica of the 
lipopolyplexes, a consequence of freeze fracture technique, visualised by depositing a layer of 
platinum could be clearly seen (Figure 10. b). This gave a detailed insight into the 
morphological features of the lipopolyplexes and their distinctive spherical appearance. The 
distorted appearance of the replicas in the micrograph could be inferred to the fact that more 
than a single liposome was removed during the process of freeze fracture giving its replica a 
wrinkled appearance. 
 
3.2.1.3 Transmission electron microscopy 
To elucidate the structure of lipopolyplexes and to confirm the hypothesised polyplex-in-
liposome structure, TEM analysis was performed. TEM was performed using an ultra-high 
resolution microscope equipped with a tungsten cathode capable of delivering 300 kV of 
accelerating voltages. For the sample preparation, a heavy metal salt, uranyl acetate was 
employed. At lower concentrations, uranyl acetate acts as a negative stain. Due to its high 
electron density, its interaction with the incident electron beam is minimal, therefore creating 
its signature dark background against a light sample which greatly enhances the contrast. 
Carbon coated copper grids were used for TEM due to better mechanical strength compared to 
uncoated copper grids. Mounting of hydrophilic lipopolyplexes onto hydrophobic carbon 
coated grids effects sample preparation, since much of the sample is easily washed away. 
Therefore, the grids were glow discharged to render them hydrophilic. Since lipopolyplexes 
were present in buffered aqueous solutions, the grids with samples were carefully washed with 
water to remove excess of buffer before negative staining with uranyl acetate. At the low 
concentration used in this study, uranyl acetate does not react with the samples and acts only as 
a background contrast enhancer.  
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Figure 11: TEM micrographs of a.) lipopolyplex containing gold coupled PEI polyplex (with 
pictorial representations of the same) and b.) gold coupled PEI polyplex  
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Coupling of PEI with gold created the opportunity to visualise within the lipopolyplex.  Gold 
particles are easily visible under an electron microscope. Therefore, 20 nm gold spheres were 
used for coupling with thiolated PEI. Polyplexes could be easily identified due to the presence 
of gold nanospheres (Figure 11. a). The hypothesis of a composite nanocarrier system i.e. the 
presence of a polyplex inside a liposome was confirmed with the micrograph showing electron 
dense gold coupled PEI inside a liposomal structure (Figure 11. b). The illustration of the 
lipopolyplex represents the arrangement of the gold labelled polyplexes inside the liposomes 
giving a clear picture about the actual structure. The size range of both polyplexes and 
lipopolyplexes could be confirmed with the TEM micrographs.  
 
3.2.2 Atomic Force Microscopy 
To better understand the surface characteristics of lipopolyplexes, atomic force microscopy was 
employed. The advantage of atomic force microscopy over other microscopic techniques is the 
interaction of the scanning tip with the sample thereby giving a clear picture of the actual 
structure of the sample including minute details. This form of microscopy enables resolution at 
atomic levels allowing further interpretation of the samples. However, without substantial 
knowledge about the operation of an AFM, hardness of the cantilever, composition, coating and 
physical characteristics of the scanning tip it is quite impossible to obtain perceivable 
micrographs. This often leads to formation of artefacts and misinterpretation of the results.  
 
Since AFM is a surface scanning technique which employs a pyramidal scanning tip (composed 
of metal or metal alloys) moving across the surface of the sample, soft samples involving 
liposomes are often damaged. Liposomal formulations often tend to stick to the scanning tip 
leading to artefacts on the digitally transformed image. To avoid this, intermittent contact mode 
(also referred to as tapping mode) was used for scanning the lipopolyplexes. In this mode, the 
piezo element of the cantilever holder constantly oscillates up and down at amplitudes in the 
range of nanometres. The tip of the cantilever scans close enough to the sample without actually 
touching it. Electrostatic forces, dipole-dipole interactions and van der Waals forces cause the 
amplitude of the tip to change, this change is detected and transformed digitally into a 
micrograph [151, 152]. Lipopolyplexes were image using intermittent contact mode to prevent 
damage to the liposomal surface.  
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Similar to SEM, the samples were let dry on a silica wafer followed by washing steps for 
visualisation under an AFM. Due to this process, the lipopolyplexes tend to clump together 
forming pseudo-aggregates. AFM micrograph shows individual lipopolyplexes which are 
distributed freely together clusters of lipopolyplexes attached to each other or stacked above 
each other (Figure 12). The lipopolyplexes exhibit a smooth, round shape which is a 
characteristic of its parent liposomes. The shape of lipopolyplexes is in agreement with 
previously conducted studies confirming the structure of lipopolyplexes [18, 75].  Comparison 
of electron microscopy images with that of AFM show a clear correlation between the shape 
and size of lipopolyplexes across the imaging techniques used. The size of the images from the 
micrographs is in clear agreement with the size obtained from DLS results. The positive zeta 
potential obtained regardless of the anionic liposomes used points towards an excess of positive 
charge of PEI radiating outside the liposomal bilayer. Backed by the data obtained from the 
physicochemical, structural and morphological characterisations, it could be confirmed with 
certainty that the PEI polyplexes sit inside the liposome. 
 
 
 
 
Figure 12: Topographic pseudo-coloured AFM micrograph of linear PEI lipopolyplexes 
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3.3 Stability studies 
In order to deliver the genetic material into the cells, gene delivery vehicles need to be able to 
protect the cargo from extracellular and intracellular degradation, most importantly against 
nucleases. The main reason for the decrease in the biological activity is due to insufficient 
protection of the nucleic acids. Premature degradation of the delivery vehicles in biological 
fluids often exposes the nucleic acids to nucleases which has a detrimental effect on the delivery 
efficiency. Delivery vehicles, on the other hand should be able to release their cargo at the site 
of action, failing to do so would also result in a loss in the biological activity and delivery 
efficiency. Therefore, delivery vehicles should be formulated in such a manner so that they 
effectively prevent their cargo against degradation, and readily release the cargo at the site of 
action.  
 
3.3.1 Complex integrity 
To confirm the condensation of pDNA with PEI, gel retardation assay was performed on 1 % 
agarose gels containing ethidium bromide as a DNA intercalator. Different charge ratios of lPEI 
and bPEI were used to analyse the interactions between pDNA and PEI.  
 
 
 
Figure 13: Gel retardation assay of the branched and linear PEI polyplexes and lipopolyplexes 
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The results obtained from the assay show that condensation efficiency of bPEI is less than that 
of lPEI (Figure 13). Even at an N/P ratio of 10, bPEI polyplexes release certain amount of 
pDNA whereas lPEI polyplexes are intact showing no signs of pDNA leakage. At an N/P ratio 
of 6, lPEI polyplexes showed leakage of a fraction of pDNA which was still less than the N/P 
ratio 10 of bPEI. A complete retardation of the mobility of the pDNA could be seen in case of 
both bPEI and lPEI lipopolyplexes, suggesting a more efficient protection of the cargo.  
 
3.3.2 Complex dissociation assay 
To simulate physiological conditions, heparin assay was performed. Biological fluids, 
especially blood, which directly interacts with gene delivery vehicles comprises of a lot of 
polyanions which may be undermine the stability of the complexes. To reproduce this effect, 
heparin, a naturally occurring competing polyanion was used. 
 
 
 
Figure 14: Heparin competition assay of branched and linear PEI polyplexes and 
lipopolyplexes 
 
Being a polyanion, heparin competes with the complexes and displaces the condensed DNA. 
The data obtained from the assay, suggests lipopolyplexes to be far more stable in the presence  
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of polyanions compared to polyplexes from lPEI and bPEI (Figure 14). The lPEI polyplexes 
also show better stability than those of bPEI. bPEI polyplexes showed the least stability in 
presence of heparin.  All the complexes released pDNA in presence of 20 IU/100 mL of heparin 
(1 mg = 100 IU) but the amount of pDNA released by the lPEI lipopolyplexes was the lowest. 
Lipopolyplexes were stable at normal concentration range of heparin in a healthy adults i.e. 15-
17 IU/100 mL [153]. The outcome of this assay suggests that the liposomal layer around the 
polyplexes is offers better protection against heparin.  
 
3.3.3 Binding affinity assay 
Binding affinity of ethidium bromide to pDNA was measured as a function of complex 
integrity. To quantify the amount of free pDNA or prematurely released pDNA from the 
complexes intercalation assay was performed using fluorescence spectroscopy.  
 
 
Figure 15: Ethidium bromide intercalation assay of DOPE:DPPC:Cholesterol (DDC) 
lipopolyplexes and polyplexes.  
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As seen in the graph, a shift in the fluorescence intensity is observed in case of lipopolyplexes, 
pointing towards an increased complexation of the genetic material inside (Figure 15). DDC-
lPEI-pDNA (N/P 9.5) lipopolyplexes stored at room temperature also tested negative for DNA 
release. Interestingly the lipopolyplexes were found to be intact even after a week of storage 
showing no DNA release. The background fluorescence of an empty well was subtracted from 
the results and the fluorescence is reported as a % of free pDNA bound with ethidium bromide. 
The data obtained is compatible to the theory that a finite number of ethidium bromide binding 
sites in DNA that become gradually unavailable with increasing complexation [154].  
 
3.4 In vitro studies 
In vitro experiments offer a first line of testing for any new delivery system which is intended 
to be utilised in an organism. In an era where in vivo studies are strictly regulated, procuring a 
grant for the same is often cumbersome. Taking into consideration the ethical issues involved 
with animal studies, in vitro studies with suitable models offer a convenient solution as a 
preliminary step in evaluating any new delivery vehicle. In vitro studies are a cost-effective 
solution which asses the performance of the delivery vehicles in a more direct manner. In terms 
of anti-cancer gene therapy, investigating the tumour cells of their respective tissues is an 
excellent way to evaluate the efficacy of delivery system on the particular tumour. Artificially 
inducing inflammation using inflammatory factors in cells is has been used to study 
inflammatory effects in cells [135]. This approach was employed in this work to evaluate the 
anti-inflammatory gene therapy using lipopolyplexes as delivery vehicles.  
 
3.4.1 Transfection 
A direct method of assessing the efficiency of gene delivery vehicles is through transfection 
experiments. Transfections involve introduction of a nucleic acids into cells via delivery 
vehicles to alter their genetic sequence or to up or down-regulate certain cellular expressions. 
In this study, a plasmid DNA pCMV-luc encoding for firefly luciferase upon successful 
integration with the host DNA was used. Luciferase expression could be monitored using 
bioluminescent assays and is a direct measure of the efficiency of the gene delivery vehicles. 
Since expression of transfected gene in the cells is dependent on several factors such as cell 
health, mycoplasma contamination, cell growth phase, passage number, the results are almost 
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always irreproducible. Hence all the above factors need to be taken into consideration while 
evaluating the results. 
 
Polyplexes prepared using various N/P ratios were evaluated in terms of transfection efficiency. 
The results were consistent with the studies conducted previously in this regard [67, 155]. Data 
from the polyplexes, suggested than an N/P ratio of 9.5 and 15 for lPEI and bPEI respectively 
were appropriate for further complexation experiments with liposomes.  
 
 
 
Figure 16: Transfection efficiency of bPEI polyplexes and lipopolyplexes in SK-OV-3 cells.  
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bPEI polyplexes with an N/P ratio of 15 were used to form lipopolyplexes with both DODC 
and DDC liposomes. DDC lipopolyplexes showed better transfection compared to DODC 
lipopolyplexes with bPEI (Figure 16). The increase in the transfection efficiency with DODC 
lipopolyplexes compared to bPEI polyplexes was not significantly high. 0.2 µg of pDNA per 
well was found to be effective for both the complexes.  
 
 
 
Figure 17: Transfection efficiency of lPEI polyplexes and lipopolyplexes in SK-OV-3 cells.  
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lPEI complexes show better transfection efficiency than their bPEI counterparts. As was the 
case with bPEI DODC lipopolyplexes, lPEI DODC lipopolyplexes were also much less 
efficient than DDC lipopolyplexes (Figure 17). Transfection efficiency has increased at least 
twofold upon addition of DDC liposomes. A liposome/PEI mass ratio of 1.2 for DDC and 3 for 
DODC lipopolyplexes was used for the initial experiments. Since DDC lipopolyplexes have 
been far more efficient than their DODC counterparts, they were solely used for the further 
experiments. Higher pDNA amounts yielded better transfection results with polyplexes, but the 
results were inconsistent. Furthermore, unbound free pDNA has been proven toxic to the cell 
in previous studies, and hence the concentration was kept as low as possible without 
compromising the transfection efficiency [156].   
 
 
 
 
Figure 18: Optimisation of the liposome/PEI mass ratios of DOPE/DPPC/Cholesterol-linear 
PEI lipopolyplexes  
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Subsequent experiments involved optimising the stoichiometry of the DDC lipopolyplexes ( 
 
Figure 18). The experiments started off with a liposome/PEI mass ratio of 1.2 and then 
proceeded in decreasing ratios until an optimal ratio was achieved. After a series of experiments 
with different ratios, the mass ratio of 0.39 which showed a tenfold increase in transfection 
efficiency was deemed to be optimal. This suggests that at this ratio, the number of liposomes 
available to complex with the polyplexes was optimal. As seen in the graph, above this ratio, 
there is a decrease in the transfection efficiency, similar is the case with ratios below 0.39. This 
might be pointing towards an abundance or deficit of liposomes available for complexation, 
which was also seen in previous studies [75]. This ratio was therefore used in all subsequent 
experiments involving lipopolyplexes. 
 
To confirm the transfection and to determine the transfection efficiency of lipopolyplexes in 
other tumour cells lines which would be used for knockdown experiments. HeLa, EA.hy926 
and A549 cells were used 
 
 
Figure 19: Transfection efficiency across various cells lines with linear PEI lipopolyplexes 
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Results from the transfections in various cells lines show that transfection efficiency varies 
across cell lines (Figure 19). Not just the delivery vehicle, but also the cells play an important 
role in the transfection efficiency. Factors such as the promoter used in the plasmid, size of the 
promoter sequence also play a role in expression of reporter gene. This is in agreement with a 
previous studies mentioning the role of promoter, transgene and cell line in determining the 
transfection efficiency [157]. Delivery vehicles need to be optimised to efficiently transfect 
across different cell lines for e.g. by attaching the delivery vehicles with ligands or antibodies 
depending upon the cells. Therefore, it is almost impossible to formulate a delivery vehicles 
which works with equal efficiency across all cell lines. 
 
3.4.2 Uptake pathway analysis 
The major internalisation route for non-viral gene delivery vehicles into the cells is through 
endocytosis. In endocytosis, a part of the cell membrane engulfs the delivery vehicle which is 
either electrostatically attached to cell membrane or is in the vicinity of the cell.  Subsequently, 
a vesicle comprising membrane components, detaches off from the cell membrane and enters 
the cytoplasm to form an endosome. It is this vesicle the delivery system needs to overcome in 
order to be released into the cell. Different forms of endocytic pathways exist and different 
delivers vehicles utilise different pathways to enter the cell. The use for inhibitors for individual 
pathways helps understand the exact mechanism of cellular internalisation of the delivery 
vehicles. In this work, several different inhibitors of endocytic pathways were utilised. 
Dynasore, an inhibitor of dynamin 2 protein, interferes with the dynamin dependent 
endocytosis. Filipin III derived from Streptomyces filipensis was used as an inhibitor for 
caveolae mediated and lipid-raft mediated endocytosis and chlorpromazine was used for 
inhibiting clathrin mediated endocytosis.  
 
The exact internalisation pathway and the mechanism of uptake could be identified using the 
inhibitors. Since serum has a detrimental effect on the inhibitory effects, experiments were 
conducted in its absence. To rule out any possible interaction of complexes with inhibitors, the 
cells were washed prior to incubation with complexes. Due to their dose dependent toxicity, 
inhibitors were used in concentrations reported to be safe in previous studies [75]. 
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Figure 20: Transfection in SK-OV-3 cells in presence of specific endocytosis pathway inhibitors  
 
Transfection efficiency of cells without inhibits was considered as 100 % and the results are 
expressed in correspondence to untreated cells. Results obtained from pathway analysis in  
SK-OV-3 cells show a certain level of reduction in the transfection efficiency of lipopolyplexes 
in presence of all the three inhibitors (Figure 20). In agreement with previous studies, the 
transfection efficiency of lipopolyplexes decreased in the presence of chlorpromazine, 
suggesting a clathrin mediated internalisation pathway [75]. Additionally, lipopolyplexes also 
seem to be internalised by dynamin dependent endocytosis. Internalisation of polyplexes, 
appears to occur mainly via clathrin mediated endocytosis. The data from polyplexes is however 
ambiguous with respective to their inhibition compared to other studies reporting a dose 
dependent inhibition via all major pathways [158]. As such, the uptake mechanism is dependent 
on the cell line and hence the data should be regarded cautiously. Studies reporting the uptake 
mechanism of PEI are conflicting in terms of internalisation pathway. Schäfer et. al reported a 
caveolae independent mechanism of uptake for PEI in SK-OV-3 cells whereas another study 
by Gabrielson et.al reported a caveolae dependent endocytosis of PEI in HeLa cells [75, 159].  
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As reported previously, pathway inhibitors appear to have a non-specific mechanism to 
inhibition which is influenced by several factors, therefore, the data obtained needs to be 
interpreted with caution [160]. It can be inferred from that results that lipopolyplexes only 
utilise the clathrin mediated endocytosis but also dynamin dependent endocytosis which gives 
them an edge over polyplexes in terms of internalisation.  
 
3.5 Physical methods of enhancing gene transfer 
The data obtained from pathway analysis prompted the investigation of a suitable method for 
improving the release of the lipopolyplexes from the endosome. In general, only a fraction of 
delivery vehicles reach the target cells, of these a fraction makes it into the cells and a fraction 
of the internalised vehicles escape the endosome. To enhance this endosomal escape, light and 
ultrasound have been made used in this work. While administering light is a minimally invasive 
technique, ultrasound is a completely non-invasive technique.  
 
3.5.1 Photo-chemical internalisation 
With an aim at improving the endosomal release, through light, curcumin loaded liposomes 
were used for the complexation with polyplexes. PCI mediated introduction of luciferase 
reported gene has been studied using a compact portable prototype LED device designed for 
photodynamic studies in multiwell plate formats [133]. The irradiation intensity used for the 
PCI experiments was completely harmless to the cells. The irradiation device used for this work 
sits onto microtiter plates covering the entire surface. By varying the current intensity and time, 
irradiation dose could be adjusted. In previous studies, gene delivery vehicles and 
photosensitisers have been administered individually or chemically linked to the delivery 
vehicle [94, 97, 98]. This work involves a composite delivery system, capable of introducing 
both the photoactive agent and the genetic material together.  
 
Irradiation was performed after incubating the cells for 4 h with curcumin loaded lipopolyplexes 
and lipopolyplexes, taking into consideration the average time for endocytosis (1 - 4 h) [161]. 
Luciferase assay of the irradiated cells showed at least a threefold increase in the transfection 
efficiency upon irradiation (Figure 21). Different irradiation intensities yielded different results. 
This was in consistence with previous studies reporting the influence of irradiation dose on PCI 
[162]. An intensity of 1 J/cm2 proved to be the best in terms of transfection efficiency.  
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Un-irradiated cells (dark) containing curcumin lipopolyplexes did not show any increase in the 
transfection efficiency, clearly indicating that the increase in the transfection efficiency was 
related to irradiation. Similarly, lipopolyplexes without curcumin also did not show a difference 
in transfection efficiency upon irradiation, pointing towards the PCI effect mediated by 
curcumin. The results suggest an endocytic vesicle permeabilisation upon irradiation of cells 
internalised with curcumin loaded lipopolyplexes. Similar effects were observed in previous 
studies, studying co-delivery of photosensitiser and genetic material [94, 98]. 
 
 
 
 
Figure 21: Comparison of photo-enhanced effects on curcumin loaded linear PEI 
lipopolyplexes and lipopolyplexes (0 denotes unirradiated cells) 
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3.5.2 Ultrasound enhanced gene transfer 
Similar to photo-chemical internalisation, UEGT is a physical method aimed at enhancing gene 
transfer. Studies pertaining to UEGT have suggested that UEGT works by creating reversible 
cavities (cavitation) in the cell membrane allowing gene transfer [163, 164]. A prerequisite for 
this, however is the presence of gas filled microbubbles or gas filled particles that are sonogenic 
(acoustically active) [103, 109]. Lipopolyplexes were evaluated for their gene transfer potential 
using ultrasound. 
 
 
 
Figure 22: Ultrasound enhanced gene transfer at different time periods in SK-OV-3 cells with 
ultrasound application at different time intervals 
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Figure 23: Ultrasound enhanced gene transfer in PCS-100-012™ cells with ultrasound 
application at different time intervals 
 
The linear transducer used in the UEGT experiments was capable of delivering ultrasound at a 
frequency of 15 Mhz. Penetration depth was adjusted to 1.1 cm which was the gap between the 
surface of the petri dish and the position of the transducer (in growth medium). During the 
UEGT experiments, the mechanical index, which is a measure of the bio-effects cavitation, was 
at 1.5 which is below the maximum allowed level recommended by the regulatory authorities 
in Europe [165].  
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The results obtained from the UEGT experiments were unexpected regarding the timing of 
ultrasound exposure. Immediate exposure to ultrasound after incubation did not yield any 
benefit in SK-OV-3 cells (Figure 22). On the contrary, exposure to ultrasound after 1 and 4 h 
time periods yielded a significant increase in the transfection efficiency, with exposure after 4 
h showing a fivefold increase.  
 
In case of primary PCS-100-012™ aortic smooth muscle cells, transfection was improved after 
ultrasound exposure following 1 h of incubation with lipopolyplexes (Figure 23). Ultrasound 
exposure following 4 h incubation was not as effective as with SK-OV-3 cells. The results not 
only suggest a faster internalisation mechanism of PCS-100-012™ cells but also point towards 
a different uptake pathway. The transfection efficiency of polyplexes with or without ultrasound 
was relatively low in PCS-100-012™ cells (data not shown). 
 
The results point towards an improved release from the endosome similar to PCI experiments. 
A cavitation effect could be excluded since no substantial effect was observed upon ultrasound 
exposure soon after incubation. Comparable results proposing an endosomal rupture were seen 
in another study suggesting the influx of Ca+ ions into the cell upon ultrasound exposure leading 
to endosomal acidification and subsequent release [166]. This, was however, not the case with 
polyplexes which did not show any substantial improvement at all, leading to ambiguity in the 
exact mechanism of action.  
 
3.6 Transfection visualisation 
To observe the intracellular expression of the reporter gene, and to confirm the transfection 
efficiency using a different reporter gene system, pEGFP-N1 plasmid DNA expressing green 
fluorescence protein was used. Expression of GFP was visualised using confocal laser scanning 
microscopy.  
 
Micrographs from the cells transfected with lipopolyplexes and polyplexes show successful 
GFP expression (Figure 24). DAPI was used to counterstain the nuclei in order to localise the 
cells during microscopy. Compared to the micrographs of polyplexes, the micrographs of 
lipopolyplexes show more number of cells expressing GFP. The amount of GFP expressed per 
cell (qualitatively) is also higher in case of lipopolyplexes.  
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Both polyplexes and lipopolyplexes have successfully entered the cells and have undergone 
intracellular dissociation to release pEGFP-N1 which has successfully transcribed and been 
translated into green fluorescence protein.  
 
 
 
Figure 24: Visualisation of GFP expression in SK-OV-3 cell transfected with linear PEI 
polyplexes and lipopolyplexes; scale bar 20 µm 
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3.7 Knockdown studies 
An ideal gene delivery vehicle should be able to deliver various kinds of nucleic acids with 
considerable efficiency. Most commercially available gene delivery vehicles, termed 
transfection reagents, fall short in this aspect. Most manufacturers offer different transfection 
reagent for different nucleic acids and to further complicate things, different transfection 
reagents for different cell lines are offered. Transfections with siRNA is cumbersome with 
regard to the special needs in terms of equipment and reagents. An RNAse free environment is 
required to rule out the effect of the nucleases on the siRNA. Buffers, reagents, equipment that 
comes into contact with the siRNA should all be RNAse free to ensure reliable results. Only 
the complexation buffer (10 mM HEPES; pH 7.4) and the pipette tips used in this work were 
RNAse free.  
 
 
Figure 25: RNA interference in luciferase expressing SK-OV-3-luc and HeLa luc+GFP cell 
lines 
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To assess the RNAi potential of the delivery vehicles, a stable luciferase expressing SK-OV-3 
cell line and a HeLa cell line co-expressing luciferase and GFP was used. siRNA often leads to 
off-target effects complicating the interpretation of results. To determine the siRNA activity 
without misinterpreting the results, appropriate controls should be used. In this work, a control 
siRNA siCtrl with no human or animal targets was employed. To target the GL3 luciferase gene 
in SK-OV-3-luc cells, luciferase GL3 duplex siRNA was used. In case of HeLa luc+GFP cells 
expressing firefly luciferase, Anti-luc siRNA 1 was used.  The two cell lines showed different 
luciferase activity upon siRNA transfection. In a stark contrast with transfection experiments, 
where the difference in luciferase activity between SK-OV-3 and HeLa cells was huge, 
knockdown experiments yielded different results (Figure 19 and Figure 25). If the results of the 
HeLa were to be considered, knockdown efficiency in SK-OV-3 was greater compared to its 
transfection efficiency. This should however, be interpreted with caution due to the different 
mechanisms of action. Plasmid DNA needs to make its way to the nucleus in order to induce 
gene expression. The target biomolecule for siRNA is its complimentary mRNA which is 
transcribed into the cytosol, making it an easier target [167]. In terms of knockdown efficiency, 
the lipopolyplexes showed a far better transfection efficiency compared to lPEI polyplexes 
which were marginally better than their bPEI counterparts. 
 
In order to replicate the knockdown efficiency using a target gene, endothelial EA.hy926 cells 
were used. Endothelial cells express E-selectin as an inflammatory response. In this work, 
inflammation was induced using TNF-α. E-selectin, an endothelial leukocyte adhesion 
molecule, plays a major role inflammation. As a response to inflammation, endothelial cells 
express E-selectin, which mediates leukocyte binding and subsequent infiltration (extravasation 
into the inflamed tissue [113]. This mechanism of E-selectin is exploited by the tumour cells to 
mimic the leukocytes and metastasise. Several studies also suggest that tumour cells might 
directly express factors and selectin ligands that induce E-selectin expression leading to a chain 
reaction. This in turn is associated with progression of tumours and infiltration of migrating 
cancer cells through endothelial vessels [168-171]. These factors make E-selectin an important 
therapeutic target to counter inflammatory diseases and inflammation associated tumour 
metastasis.  
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Figure 26: E-selectin knockdown in EA.hy926 cells, with two different siRNA directed against 
E-selectin 
 
ELISA experiments following incubation of EA.hy926 cells with lipopolyplexes containing 
two different types of siRNA’s yielded contrasting results. As a control a scrambled siRNA, 
siCtrl was used and as positive control for transfection, commercially available siRNA 
transfection reagent INTERFERin® was used. While the double stranded siRNA against SELE 
gene showed a slight reduction on E-selectin expression, the 27mer Trilencer dsiRNA showed 
a dramatic reduction in the expression (Figure 26). This points towards the role of dsiRNA in 
processing the siRNA post transfection, which is consistent with the studies reporting its 
improved role in RNAi compared to siRNA [172, 173].  Compared to the commercial siRNA 
transfection reagent, the lipopolyplexes showed better knockdown, especially with dsiRNA.  
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Although no strict RNAse free conditions were maintained (due to practical restrictions viz. 
extrusion equipment, glassware and other consumables) during the preparation of liposomes  
and PEI for the experiments, the RNAi studies with lipopolyplexes still showed significant 
bioactivity, pointing towards the role of lipopolyplexes from preventing the siRNA from 
degradation against nucleases. 
 
3.8  In vitro Cytotoxicity studies 
A major aspect in delivery of biomolecules, often understudied is the toxicity of the delivery 
vehicles. Cytotoxicity is the main obstacle for utilising non-viral gene delivery vehicles for a 
therapeutic setup. Toxicity studies help assess the safety of the delivery vehicles. Determination 
of a safe dose or a safe concentration could be done using toxicity tests. Toxicity of delivery 
vehicles could be both immediate or dependent on time. LDH and MTT assays have been used 
to determine the acute toxicity and time dependent toxicity of the complexes respectively. 
 
3.8.1 Membrane toxicity 
LDH assay measures the amount of lactose dehydrogenase released by cells into the medium 
(following cell membrane damage) as a measure of cytotoxicity. This usually occurs during the 
initial incubation period with the delivery vehicles. Most commercial non-viral vectors suggest 
changing the medium 4 h after incubation with cells to reduce the cytotoxic effect of the 
delivery vehicles. For this work, however, the medium was left until the time point of 
evaluation. Therefore, for the LDH assay, L929 cells were incubated for 48 h with the 
complexes.  
 
Severe damage to the cell membrane could be seen in case of bPEI polyplexes (Figure 27). This 
is in agreement with previous studies linking the high charge density of PEI to cell membrane 
destabilisation and cellular necrosis [78, 79]. In case of lPEI polyplexes, cytotoxicity was 
considerably lower than its branched counterpart, which is in consistence with studies 
comparing the cytotoxicity of branched and linear polyethylenimine [174, 175]. Comparatively, 
lipopolyplexes formulated using bPEI were more cytotoxic than their linear counterparts, which 
were minimally cytotoxic. This could be attributed to the shielding effect liposomes impart to 
the polyplexes. As reported previously, the cytotoxicity of PEI is mainly due to its cationic 
charge density [79]. Liposomal encapsulation, especially with anionic liposomes, is an 
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outstanding approach in reducing the surface charge of PEI, without complex structural 
modifications and without compromising its transfection efficiency.  
 
 
 
Figure 27: LDH assay of polyplexes and lipopolyplexes with branched and linear PEI. Triton 
X-100 ™ used as positive control. 
 
3.8.2 Time dependent cytotoxicity 
MTT assay was used to determine the cell viability as a function of time. Viable cells metabolise 
MTT into formazan crystals, which upon solubilisation with DMSO could be measured 
spectrophotometrically. To get a deeper insight into the time related toxicity of the complexes, 
MTT assay was performed after 4, 8, 16, 24, 36 and 48 h. L929 cells incubated with complexes 
were assayed at the aforementioned time periods to determine the cell viability. 
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Figure 28: Cell viability of branched and linear PEI polyplexes and lipopolyplexes at time 
intervals ranging from 4 to 48 h 
 
Similar to LDH assay results, MTT results show the highest toxicity in case of bPEI (Figure 
28). The toxicity effect of bPEI is seen within 4 h of incubation, confirming the charge related 
cell membrane degradation reported previously [78]. This was similar in case of lPEI too, 
however, to a lesser extent. Viability of bPEI lipopolyplexes was less than their lPEI 
counterparts, but better than that of lPEI polyplexes. lPEI lipopolyplexes showed the highest 
cell viability even after 48 h of incubation. Viability of all the complexes inversely proportional 
to time, decreasing gradually with increasing incubation periods. The difference in the initial 
toxicity at 4 h in between polyplexes and lipopolyplexes confirms the liposomal shielding 
effect. The results of the cytotoxicity studies are consistent with a previous study reporting the 
liposomal shielding of PEI [75].  
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3.9 Haemocompatibility studies 
Haemocompatibility studies offer an excellent platform in determining the compatibility of any 
non-viral delivery system. In vitro cytotoxicity tests give only a partial picture of the 
cytotoxicity scenario, which is limited to cells. Upon delivery, the first point of contact for non-
viral vectors is blood. Blood is a mixture of a multitude of constituents. Interaction with the red 
blood cells or erythrocytes is a critical factor which determines the biocompatibility of delivery 
vehicles. Similarly, the delivery systems should also be compatible with the plasma, a major 
component of blood, containing clotting factors. Any unmonitored alteration to the pathways 
of haemostasis could have deleterious effects on the patient. Therefore, a clear understanding 
of the interaction of the delivery vehicles with blood is important in deeming a delivery system 
biocompatible. Haemocompatibility tests are also a bridge between in vitro and in vivo studies, 
wherein, they help determine the safe and ethical use of the delivery vehicles, saving a lot a of 
time, personnel and investment. 
 
3.9.1 Haemolysis assay 
Erythrocytes are the building blocks of the complex human biological system. They contain 
haemoglobin, which plays a vital role in the transport of oxygen and CO2, to and from the 
tissues. Haemolysis assay give the measure of damage to the erythrocytes, by measuring the 
amount of haemoglobin released. Haemoglobin from the erythrocytes, binds with oxygen to 
form oxyhaemoglobin, whose absorbance could be recorded spectrophotometrically at 540 nm.  
 
1 % Triton X-100™ was used as positive control for haemolysis due it ability to completely 
lyse the cells [176]. The absorbance values of oxyhaemoglobin from Triton X-100™ samples 
were considered as 100 % cell lysis. Due to its high charge density, bPEI polyplexes, readily 
lysed the erythrocytes leading to a release in haemoglobin (Figure 29). Interestingly, lPEI 
polyplexes showed a much less haemolytic potential, pointing towards a charge related lysis 
haemolytic effect of bPEI. Once again, encapsulation of the polyplexes with liposomes proved 
beneficial with both bPEI and lPEI lipopolyplexes. The haemolysis effect observed with 
lipopolyplexes is very low and taking into consideration, the ratio (v/v) of erythrocytes to 
injected delivery vehicles in the human body, is negligible.  
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Figure 29: Haemolysis assay of the complexes, complexes showing haemolysis of above 20 % 
(untreated blood) were considered to show haemolytic potential 
 
3.9.2 Activated partial thromboplastin time test 
Normally a diagnostic tool for monitoring patients undergoing anticoagulant therapy, the aPTT 
test is valuable in determining the effect of the delivery vehicles on coagulation. Although a 
deviation from normal aPTT values does not pose immediate risk, when unmonitored, could 
prove fatal on a long run. aPTT test is often neglected and very rarely utilised in 
biocompatibility studies. With the aim of developing an efficient delivery system which is also 
biocompatible, aPTT test was performed in this work to determine the effect of the complexes 
on coagulation.  
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Figure 30: Activated partial thromboplastin time test of the complexes. Coagulation times 
between 30 and 40 s are considered normal, with above 45 s suggesting considerable 
interference with coagulation 
 
Fresh blood plasma was used to determine the aPTT values. aPTT time of blood plasma was 
measured to be 32 ± 0.1 s and was found to be in the normal range [177]. Values between 30 -
40 s are considered acceptable and values above 70 s signifies spontaneous bleeding [137]. The 
aPTT time for bPEI polyplexes was higher than all the other complexes (Figure 30). This 
confirms the results obtained from toxicity and haemolysis tests, showing branched PEI 
polyplexes to be sparingly biocompatible. Both lPEI polyplexes and lipopolyplexes did not 
interfere with the coagulation time. Similar to the haemolysis assay, use of liposomes to 
encapsulate the polyplexes, reduced the aPTT time. This effect, however, was pronounced in 
case of bPEI polyplexes. It is worthwhile to mention that the lipopolyplexes, performed well in 
both toxicity and haemocompatibility tests, thereby proving its biocompatibility. 
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3.10 In vivo chick chorioallantoic membrane  
In most cases, testing of delivery vehicles on animal models is quite inappropriate considering 
the ethical issues. Studies often directly use an animal models without performing specific in 
vitro and ex vivo tests, which give a picture of the biocompatibility of the delivery vehicles. In 
vitro efficiency and toxicity, in many cases in not reproducible with in vivo conditions. 
Therefore, a need for an alternative, which help reduce the animal tests is of utmost importance. 
The chick chorioallantoic membrane model offers an excellent ethical and cost effective 
alternative predictive platform. Several studies have used the CAM model for studying 
biomaterials, angiogenesis, tumour growth and tissue engineering [127, 129, 178, 179]. In this 
work, CAM model has been utilised to determine the efficacy and toxicity of the lipopolyplexes 
in vivo.  
 
 
 
Figure 31: CLSM micrograph showing GFP expression in a CAM section 48 h post transfection 
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Transfection of the CAM model was performed by injecting 100 µL of lPEI lipopolyplexes 
(N/P 9.5) containing 0.8 µg of pEGFP-N1 on egg development day 11 (EDD 11). On EDD 13 
the CAM layer cut out and observed for green fluorescent protein expression under a CLSM 
(Figure 31). The image shows GFP expression in what appears to be epithelial cells of the 
CAM. The pronounced expression of GFP is seen in almost each and every cell of the 
micrograph. Although other layers of CAM also showed GFP expression, due to practical 
limitations, a clear micrograph of the transfected inner layers of the CAM was not possible. 
 
For the toxicity studies, 6 eggs were injected with LPPs (lPEI; N/P 9.5) containing 2 µg of HT-
DNA into the blood vessels on EDD 11, the eggs were observed at regular intervals until the 
time point of appearance of distinct biological structures. No toxicity, or retardation in the 
embryogenesis was observed and therefore was a confirmation that the lipopolyplexes had no 
toxic effects on the development of the egg. Together with the results from the GFP expression, 
it could be safely concluded that the lipopolyplexes maintained their transfection efficiency in 
vivo at the same time being non-toxic to the eggs. 
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Part IV: Summary and outlook  
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4.1 Summary and outlook 
Supported with a strong literature background, this thesis elaborately describes the perspectives 
of an efficient, biocompatible delivery system capable of transfecting both in vitro and in vivo 
with minimal toxicity. A detailed study of the lipopolyplexes was performed to evaluate its 
efficacy and capabilities yielding consistent results. 
 
The introduction part of the thesis deals with aspects such as gene delivery, RNA interference 
and vectors used for the delivery. Non-viral vectors, especially polymer and liposomal based 
gene delivery vehicles are reviewed. These formed the basis for the composite nanocarrier 
system, lipopolyplex used in this study. Advantages and disadvantages of liposomal and 
polymer based gene delivery systems are reviewed. Composition, structural characteristics and 
physicochemical properties of lipopolyplexes are discussed. Physical methods for enhancing 
the gene transfer using lipopolyplexes via photochemical internalisation and ultrasound 
enhanced gene transfer are described. A therapeutic anti-inflammatory model to evaluate the 
efficacy of the lipopolyplexes has been described. The necessity of toxicity and 
haemocompatibility studies for the evaluation of delivery vehicles have been summarised. 
Chorioallantoic membrane model has been described with the aim to prove the biocompatibility 
and efficacy of the lipopolyplexes in vivo.  
 
In the results part, preparation and formulation of the liposomes, polyplexes and lipopolyplexes 
has been described in detail. Physicochemical characterisation of the delivery vehicles using 
dynamic light scattering and laser Doppler velocimetry has revealed a stable, monodisperse 
formulation within the size range suitable for cellular internalisation. Influence of factors such 
as liposomal composition, N/P ratio of polyplexes, liposome/PEI mass ratio of lipopolyplexes 
and storage conditions on size and zeta potential have been described. The results obtained 
show that the lipopolyplexes are stable even after a month of storage with minimal loss in 
biological activity. 
 
To give a deeper insight into the structure of the lipopolyplexes, extensive electron microscopic 
characterisation has been performed. Morphological characteristics were described using 
atomic force microscopy. The size of the lipopolyplexes obtained by dynamic light scattering 
has been confirmed using micrographs from electron and atomic force microscopy. 
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Scanning electron micrographs show a defined spherical morphology of the lipopolyplexes 
which is a characteristic of their parent liposomes. The micrographs from the transmission 
electron microscopy using gold coupled PEI elucidate the multicomponent polyplex-in-
liposome structure of the lipopolyplexes. Freeze fracture technique has been utilised to obtain 
replica images showing structural characteristics of the lipopolyplexes. Atomic force 
micrographs confirmed the shape of the lipopolyplexes. 
 
Transfection studies have been performed to determine the efficiency of the complexes. 
Compared to the polyplexes, lipopolyplexes, especially those formulated using linear PEI 
showed a tremendous increase in expression of luciferase gene. The increased gene expression 
has been confirmed using confocal laser scanning microscopy with green fluorescence protein 
expression. The effect of photochemical enhancement has been studied using curcumin loaded 
lipopolyplexes which showed improved transfection efficiencies followed by irradiation using 
a prototype LED device. Similar effects were observed upon application of ultrasound in 
ultrasound enhanced gene transfer experiments. The potential of lipopolyplexes to be delivered 
via different methods depending on the target has been explained using physical enhancement 
methods. Applicability of such methods for delivering genetic material into difficult to transfect 
primary cells using lipopolyplexes has been reported. 
 
Toxicity studies describing the membrane damage and time dependent toxicity of the 
complexes have been discussed in detail. The membrane integrity studies compare the cytotoxic 
potential of polyplexes and lipopolyplexes. The decreased cytotoxic potential upon addition of 
liposomes to polyplexes helps understand the shielding effect of liposomes on PEI. Time 
dependent toxicity studies comparing the cell viability of cells transfected using polyplexes and 
lipopolyplexes show a substantial improvement in the cell viability upon liposomal 
encapsulation of polyplexes. 
 
Haemocompatibility studies were performed to determine the biocompatibility and potential of 
the lipopolyplexes for in vivo use. Lipopolyplexes are shown to have a decreased haemolytic 
potential compared to the polyplexes. Similarly, aPTT studies show that lipopolyplexes, on 
contrary to polyplexes, especially bPEI polyplexes, do not interfere with coagulation. The 
haemocompatibility studies revealed the lipopolyplexes to be biocompatible and therefore safe 
for intravenous administration. 
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In vivo chick chorioallantoic model (CAM) has been used as an alternative to animal models. 
The CAM studies showed that the lipopolyplexes were also able to transfect in vivo with a 
considerable transfection efficiency. The GFP expression was visualised by confocal laser 
scanning microscopy of the CAM section. The in vivo toxicity assay, wherein the 
lipopolyplexes were injected into the blood stream, show no deleterious effect on the 
development of the embryo and the egg, confirming the safety profile of lipopolyplexes. 
 
The investigations carried out in this work have shown that the combination of lPEI polyplexes 
with DOPE/DPPC/Cholesterol liposomes is a promising candidate in DNA and siRNA delivery 
both in vitro and in vivo. The liposomal shielding effect, which reduces the surface charge of 
the PEI, has been reported to be the key for the increased efficiency and low toxicity of the 
lipopolyplexes.  
 
A clear understanding into the mechanisms of action regarding photochemical internalisation 
and ultrasound enhanced gene transfer is needed to further optimise the methods. This could be 
achieved using markers for cell death pathways. Use of fluorescence probes for specific cellular 
organelles together with confocal microscopic investigations would help understand the 
enhancement mechanisms involved. Further investigation into the beneficial properties of the 
lipopolyplexes for therapeutic gene delivery could lead to the development of a safe delivery 
system for clinical purposes.  
 
Together with the reliable results and elaborate characterisation, this thesis work presents a 
potential composite nanocarrier as a worthy contender for gene therapy.  
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4.2 Zusammenfassung und Ausblick  
Die vorliegende Arbeit beschreibt ausführlich die Perspektiven eines effizienten und 
biokompatiblen Gentransfersystems, welches sowohl in vitro als auch in vivo verwendbar ist. 
Zur Überprüfung der Wirksamkeit und Einsatzfähigkeit der Lipopolyplexe wurden im Vorfeld 
eingehende physikalisch chemische Charakterisierungen durchgeführt. Einen ausführlichen 
Überblick über die potentiellen Möglichkeiten des Gentransfers, die RNA-Interferenz und 
sogenannte Nicht-virale Vektoren werden in der Einleitung gegeben. Einleitend sind zunächst 
die nicht-virale Vektoren, insbesondere die Polymer- und Liposomale Transfersysteme 
dargestellt. Diese Transfersysteme bilden die Grundlage für das zusammengesetzte, in dieser 
Arbeit vorgestellte, Nanoträgersystem „Lipopolyplex“. Anschließend erfolgt eine Diskussion 
über ihre strukturellen Eigenschaften. Moderne physikalische Methoden (Ultraschall bzw. 
Photodynamik), welche zur Verbesserung des Gentransfers mit Lipopolyplexen dienen können, 
werden ebenfalls dargestellt. Bei diesen Methoden handelt es sich insbesondere um die 
photochemische Internalisierung (PCI, Photodynamik) und der durch Ultraschall verstärkte 
Gentransfer (UEGT). Darüber hinaus wird ein therapeutisches antiinflammatorisches Modell 
zur Bewertung der Wirksamkeit von Lipopolyplexen als erster therapeutischer Ansatz 
dargestellt. Zusätzlich werden die Notwendigkeit der Toxizitäts- und 
Hämokompatibilitätsstudien für die Evaluierung von Gentransfersysteme beschrieben und 
zusammengefasst. Ein weiteres Modell, das sogenannte Chorioallantoismembran Modell 
(CAM) diente der in vivo Charakterisierung, der Biokompatibilität und der Effizienz der 
Lipopolyplexen.  
 
Die Herstellung und Formulierung von Liposomen, Polyplexen und Lipopolyplexen wurde 
ausführlich in Part II (2.2 Experiments) beschrieben. Mit Hilfe der dynamischen Lichtstreuung 
und des Laser-Doppler-Velocimetrie konnte die physikalisch-chemische Charakterisierung der 
Gentransfersysteme bestimmt werden. Die daraus resultierenden Ergebnisse ergaben eine 
stabile, monodisperse Formulierung (hydrodynamischer Durchmesser 201.1 ± 5.9; PDI 0.19) 
innerhalb der für die zelluläre Internalisierung geeigneten Größenbereiche (≤ 200 nm). Der 
Einfluss von Faktoren wie Lipidzusammensetzung, N/P-Verhältnis von Polyplexen, 
Liposom/PEI-Massenverhältnisse von Lipopolyplexen und deren Lagerbedingungen auf die 
Größe und das Zeta-Potential wurden ausführlich untersucht. Dabei wurde festgestellt, dass die 
N/P-Verhältnis einen großen Einfluss auf Zeta Potential hatte. Die Ergebnisse zeigen, dass die 
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Lipopolyplexe auch nach einem Monat Lagerung stabil sind und einen minimalen Verlust an 
ihrer biologischen Aktivität haben.  
 
Um einen tieferen Einblick in die Struktur der Lipopolyplexe zu gewinnen, wurde eine 
umfangreiche elektronenmikroskopische Charakterisierung in Kombination mit der 
Rasterkraftmikroskopie durchgeführt. Die bestimmten Größen der unterschiedlichen 
Lipopolyplexe waren innerhalb der Methoden vergleichbar. Die 
rasterelektronenmikroskopischen Aufnahmen zeigten eine definierte kugelförmige 
Morphologie, die üblicherweise für die Ausgangs-Liposomen charakteristisch ist. Die 
mikroskopischen Aufnahmen der Transmissionselektronenmikroskopie wurden unter der 
Verwendung von goldgekoppeltem PEI durchgeführt um eine Differenzierung zwischen dem 
Polymer und dem Lipid vornehmen zu können. Die entstandenen Bilder verdeutlichen die 
Mehrschichten Struktur „Polyplex-in-Liposome“ der Lipopolyplexe. Die strukturellen 
Oberflächeneigenschaften (mit Replika Technik) konnten mittels der Gefrierbruch 
Elektronenmikroskopie visualisiert werden. Die rasterkraftmikroskopischen Aufnahmen 
bestätigen die Form der Lipopolyplexe.  
 
Um die Effizienz der Komplexe (Polyplexe und Lipopolyplexe) nachzuweisen, wurden weitere 
Transfektionsstudien durchgeführt. Im Vergleich zu den Polyplexen wiesen die Lipopolyplexe, 
insbesondere die, welche mit linearem PEI hergestellt wurden, eine enorme Zunahme der 
Expression des Luciferasegens auf. Die erhöhte Genexpression konnte mittels konfokalem 
Laser-Scanning-Mikroskops durch den Einsatz von Grün fluoreszierenden Proteinexpression 
bestätigt werden. 
 
Die Wirkung der photochemischen Verstärkung (Photochemical Internalisation) wurde unter 
Verwendung von Curcumin beladenen Lipopolyplexen untersucht. Die Ergebnisse zeigten nach 
der Bestrahlung mit einer Prototyp-LED-Leuchte eine verbesserte Transfektionseffizienz. 
Ähnliche Effekte konnten bei der Anwendung von Ultraschall (Ultrasound enhanced gene 
transfer) erzeugt werden. Die Anwendbarkeit von Verfahren, die zur Bereitstellung von 
genetischem Material in schwierig transfizierbaren Primärzellen dienen, konnten unter der 
Verwendung von Lipopolyplexen bestätigt werden. 
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Membranschäden und die zeitabhängige Zytotoxizität von Komplexen wurde anhand 
verschiedenster Toxizitätsstudien festgestellt. Die Membranintegritätsstudien vergleichen das 
zytotoxische Potential von Polyplexen und Lipopolyplexen. Darüber hinaus konnte bewiesen 
werden, dass durch die Zugabe von Liposomen der zytotoxische Effekt von Polyplexen 
signifikant abnimmt. Die Ursache liegt in der Abschirmung der Ladungsdichte von PEI. 
Weitere zeitabhängige Toxizitätsstudien vergleichen die bereits mit Polyplexen und 
Lipopolyplexen transfizierten Zellen miteinander. Diese Ergebnisse zeigten eine deutliche 
Erhöhung der Zellviabilität durch die liposomale Verkapselung von Polyplexen. 
 
Hämokompatibilitätsstudien verdeutlichten die Biokompatibilität und das Potential der 
Lipopolyplexe für in vivo Verwendungen. Im Vergleich zu Polyplexen haben Lipopolyplexe 
ein deutlich vermindertes hämolytisches Potential. Ähnliche Ergebnisse zeigten die aPTT-
Studien. Lipopolyplexe beeinflussen im Gegensatz zu den Polyplexen (insbesondere bPEI-
Polyplexe), nicht die Koagulation des Blutes. Die Hämokompatibilitätsstudien zeigten, dass die 
Lipopolyplexe biokompatibel und daher für eine intravenöse Verabreichung gut geeignet sind. 
 
Das in vivo Chorioallantoismembran Modell wurde als Alternative zu Tiermodellen verwendet. 
Die CAM Studien zeigten, dass sich Lipopolyplexe auch in vivo transfizieren lassen. Diese 
wurden durch die GFP Expression in den CAM-Aufnahmen bestätigt. Die in vivo 
Toxizitätsstudien im CAM Modell mit Lipopolyplexen zeigten keinerlei schädliche Wirkung 
auf die Entwicklung des Embryos und des Eies und bestätigen damit das Sicherheitsprofil von 
Lipopolyplexen.  
 
Zusammenfassend kann eingeschätzt werden, dass die hier erstellte Kombination von lPEI-
Polyplexen und DOPE/ DPPC/Cholesterol-Liposomen ein vielversprechender Kandidat für die 
DNA- und siRNA-Transfer in einer modernen Gentherapie ist. Die Abschirmwirkung der 
Liposomen reduziert die Oberflächenladung des PEIs. Dieses Phänomen spielt hierbei eine 
große Rolle für die erhöhte Effizienz und geringe Toxizität der Lipopolyplexe.  
 
Ein besseres Verständnis der Wirkungsmechanismen, hinsichtlich der photochemischen 
Internalisierung und des ultraschallverstärkten Gentransfers sind jedoch erforderlich, um die 
Methoden weiter zu optimieren. Eine Möglichkeit wäre den Weg des Zelltodes mittels 
spezieller Markern zu ermitteln. Die Verwendung von Fluoreszenzproben für spezifische 
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zelluläre Organellen, unterstützt mit konfokalen mikroskopischen Untersuchungen bietet eine 
gute und solide Methode die beteiligten Mechanismen zu verstehen. Weitere Untersuchungen 
der positiven Eigenschaften der Lipopolyplexe könnten zur Entwicklung eines sicheren 
Abgabesystems für die klinische Anwendung des therapeutischen Gentransfers führen.  
 
Zusammen mit den hier zuverlässig erzeugten Ergebnissen und der umfangreichen 
Charakterisierung stellt diese Dissertation ein potentielles Composite-Nanocarrier-System für 
die Gentherapie dar. 
 
 89 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Part V: Appendix 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 90 
 
5.1 References 
[1] M. Collins, A. Thrasher, Gene therapy: progress and predictions, Proc Biol Sci, 282 (2015). 
[2] E. Bender, Gene therapy: Industrial strength, Nature, 537 (2016). 
[3] D.M. Dykxhoorn, D. Palliser, J. Lieberman, The silent treatment: siRNAs as small molecule 
drugs, Gene Ther, 13 (2006) 541-552. 
[4] G.D. Ferrari S, Alton EW., Barriers to and new approaches for gene therapy and gene 
delivery in cystic fibrosis, 54 (2002) 1373–1393. 
[5] F.D. Ledley, Pharmaceutical approach to somatic gene therapy, Pharm Res, 13 (1996) 1595-
1614. 
[6] R.C. Mulligan, The basic science of gene therapy, Science, 260 (1993) 926-932. 
[7] I.M. Verma, Gene therapy: hopes, hypes, and hurdles, Mol Med, 1 (1994) 2-3. 
[8] I.M. Verma, N. Somia, Gene therapy -- promises, problems and prospects, Nature, 389 
(1997) 239-242. 
[9] N. Somia, I.M. Verma, Gene therapy: trials and tribulations, Nature Reviews Genetics, 1 
(2000) 91-99. 
[10] M.S. Fox, J.W. Littlefield, Reservations Concerning Gene Therapy, Science, (1971). 
[11] A. Fire, S. Xu, M.K. Montgomery, S.A. Kostas, S.E. Driver, C.C. Mello, Potent and 
specific genetic interference by double-stranded RNA in Caenorhabditis elegans, Nature, 391 
(1998) 806-811. 
[12] S.M. Hammond, E. Bernstein, D. Beach, G.J. Hannon, An RNA-directed nuclease 
mediates post-transcriptional gene silencingin Drosophila cells, Nature, 404 (2000) 293-296. 
[13] M. Tijsterman, R.H. Plasterk, Dicers at RISC; the mechanism of RNAi, Cell, 117 (2004) 
1-3. 
[14] D.-H. Kim, M.A. Behlke, S.D. Rose, M.-S. Chang, S. Choi, J.J. Rossi, Synthetic dsRNA 
Dicer substrates enhance RNAi potency and efficacy, Nature Biotechnology, 23 (2004) 222-
226. 
[15] M. Amarzguioui, J.J. Rossi, Principles of Dicer substrate (D-siRNA) design and function, 
Methods Mol Biol, 442 (2008) 3-10. 
[16] A. Aigner, Delivery Systems for the Direct Application of siRNAs to Induce RNA 
Interference (RNAi) In Vivo, J Biomed Biotechnol, 2006 (2006). 
[17] I. Slivac, D. Guay, M. Mangion, J. Champeil, B. Gaillet, Non-viral nucleic acid delivery 
methods, Expert Opin Biol Ther, 17 (2017) 105-118. 
 91 
 
[18] A. Ewe, O. Panchal, S.R. Pinnapireddy, U. Bakowsky, S. Przybylski, A. Temme, A. 
Aigner, Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic 
siRNA delivery in vivo, Nanomedicine, (2016). 
[19] C. Janich, S.R. Pinnapireddy, F. Erdmann, T. Groth, A. Langner, U. Bakowsky, C. Wolk, 
Fast therapeutic DNA internalization - A high potential transfection system based on a peptide 
mimicking cationic lipid, Eur J Pharm Biopharm, (2016). 
[20] M.N.V.R. Kumar, U. Bakowsky, C.M. Lehr, Nanoparticles as Non-Viral Transfection 
Agents, in:  Nanobiotechnology, Wiley-VCH Verlag GmbH &amp; Co. KGaA, 2005, pp. 319-
342. 
[21] I.S. Zuhorn, V. Oberle, W.H. Visser, J. Engberts, U. Bakowsky, E. Polushkin, D. Hoekstra, 
Phase behavior of cationic amphiphiles and their mixtures with helper lipid influences lipoplex 
shape, DNA translocation, and transfection efficiency, Biophys J, 83 (2002) 2096-2108. 
[22] I.S. Zuhorn, U. Bakowsky, E. Polushkin, W.H. Visser, M.C.A. Stuart, J.B.F.N. Engberts, 
D. Hoekstra, Nonbilayer phase of lipoplex–membrane mixture determines endosomal escape 
of genetic cargo and transfection efficiency, Molecular Therapy, 11 (2005) 801-810. 
[23] M. Morille, C. Passirani, A. Vonarbourg, A. Clavreul, J.P. Benoit, Progress in developing 
cationic vectors for non-viral systemic gene therapy against cancer, Biomaterials, 29 (2008) 
3477-3496. 
[24] K. Tabatt, C. Kneuer, M. Sameti, C. Olbrich, R.H. Muller, C.M. Lehr, U. Bakowsky, 
Transfection with different colloidal systems: comparison of solid lipid nanoparticles and 
liposomes, J Control Release, 97 (2004) 321-332. 
[25] H. Yin, R.L. Kanasty, A.A. Eltoukhy, A.J. Vegas, J.R. Dorkin, D.G. Anderson, Non-viral 
vectors for gene-based therapy, Nature Reviews Genetics, 15 (2014) 541-555. 
[26] C. Kneuer, C. Ehrhardt, H. Bakowsky, M.N. Kumar, V. Oberle, C.M. Lehr, D. Hoekstra, 
U. Bakowsky, The influence of physicochemical parameters on the efficacy of non-viral DNA 
transfection complexes: a comparative study, J Nanosci Nanotechnol, 6 (2006) 2776-2782. 
[27] D.D. Lasic, Liposomes : from physics to applications, Elsevier, Amsterdam; New York, 
1993. 
[28] F. Szoka, Jr., D. Papahadjopoulos, Comparative properties and methods of preparation of 
lipid vesicles (liposomes), Annu Rev Biophys Bioeng, 9 (1980) 467-508. 
[29] M.I. Angelova, Liposome Electroformation, in:  Perspectives in Supramolecular 
Chemistry, John Wiley & Sons, Ltd., 1999, pp. 26-36. 
[30] I. Levacheva, O. Samsonova, E. Tazina, M. Beck-Broichsitter, S. Levachev, B. Strehlow, 
M. Baryshnikova, N. Oborotova, A. Baryshnikov, U. Bakowsky, Optimized thermosensitive 
liposomes for selective doxorubicin delivery: formulation development, quality analysis and 
bioactivity proof, Colloids Surf B Biointerfaces, 121 (2014) 248-256. 
[31] J. Schäfer, Liposome, in:  Corel Draw, 2010. 
 
 92 
 
[32] D.D. Lasic, F.J. Martin, Stealth Liposomes, CRC Press, 1995. 
[33] P.R. Cullis, A. Chonn, S.C. Semple, Interactions of liposomes and lipid-based carrier 
systems with blood proteins: Relation to clearance behaviour in vivo, Adv Drug Deliv Rev, 32 
(1998) 3-17. 
[34] K. Hoekstra, J. van Renswoude, R. Tomasini, G. Scherphof, Interaction of phospholipid 
vesicles with rat hepatocytes: further characterization of vesicle-cell surface interaction; use of 
serum as a physiological modulator, Membr Biochem, 4 (1981) 129-147. 
[35] G. Scherphof, F. Roerdink, M. Waite, J. Parks, Disintegration of phosphatidylcholine 
liposomes in plasma as a result of interaction with high-density lipoproteins, Biochim Biophys 
Acta, 542 (1978) 296-307. 
[36] J. Wilschut, D. Hoekstra, Membrane fusion: lipid vesicles as a model system, Chem Phys 
Lipids, 40 (1986) 145-166. 
[37] P.L. Felgner, T.R. Gadek, M. Holm, R. Roman, H.W. Chan, M. Wenz, J.P. Northrop, G.M. 
Ringold, M. Danielsen, Lipofection: a highly efficient, lipid-mediated DNA-transfection 
procedure, Proc Natl Acad Sci U S A, 84 (1987) 7413-7417. 
[38] J.T. Dingle, P.J. Jacques, I.H. Shaw, Lysosomes in applied biology and therapeutics, in: 
C. Toothill (Ed.) Lysosomes in biology and pathology, Headington Hill Hall, 1981, pp. 74-74. 
[39] I.M. Hafez, P.R. Cullis, Roles of lipid polymorphism in intracellular delivery, Adv Drug 
Deliv Rev, 47 (2001) 139-148. 
[40] F. Aqil, R. Munagala, J. Jeyabalan, M.V. Vadhanam, Bioavailability of phytochemicals 
and its enhancement by drug delivery systems, Cancer Lett, 334 (2013) 133-141. 
[41] S.S. Bansal, M. Goel, F. Aqil, M.V. Vadhanam, R.C. Gupta, Advanced Drug Delivery 
Systems of Curcumin for Cancer Chemoprevention, (2011). 
[42] V. Oberle, U. Bakowsky, I.S. Zuhorn, D. Hoekstra, Lipoplex formation under equilibrium 
conditions reveals a three-step mechanism, Biophys J, 79 (2000) 1447-1454. 
[43] L. Wasungu, D. Hoekstra, Cationic lipids, lipoplexes and intracellular delivery of genes, J 
Control Release, 116 (2006) 255-264. 
[44] I.S. Zuhorn, J.B.F.N. Engberts, D. Hoekstra, Gene delivery by cationic lipid vectors: 
overcoming cellular barriers, European Biophysics Journal, 36 (2007) 349-362. 
[45] J. Marshall, N.S. Yew, S.J. Eastman, C. Jiang, R.K. Scheule, S.H. Cheng, Cationic Lipid-
Mediated Gene Delivery to the Airways, 1 ed., Elsevier, 1999. 
[46] C.R. Dass, P.F. Choong, Targeting of small molecule anticancer drugs to the tumour and 
its vasculature using cationic liposomes: lessons from gene therapy, in:  Cancer Cell Int, 2006, 
pp. 17. 
[47] H. Lv, S. Zhang, B. Wang, S. Cui, J. Yan, Toxicity of cationic lipids and cationic polymers 
in gene delivery, J Control Release, 114 (2006) 100-109. 
 93 
 
[48] S. Khiati, N. Pierre, S. Andriamanarivo, M.W. Grinstaff, N. Arazam, F. Nallet, L. 
Navailles, P. Barthelemy, Anionic nucleotide--lipids for in vitro DNA transfection, Bioconjug 
Chem, 20 (2009) 1765-1772. 
[49] S.D. Patil, D.G. Rhodes, D.J. Burgess, Anionic liposomal delivery system for DNA 
transfection, in:  AAPS J, 2004, pp. 13-22. 
[50] J. Smisterova, A. Wagenaar, M.C. Stuart, E. Polushkin, G. ten Brinke, R. Hulst, J.B. 
Engberts, D. Hoekstra, Molecular shape of the cationic lipid controls the structure of cationic 
lipid/dioleylphosphatidylethanolamine-DNA complexes and the efficiency of gene delivery, J 
Biol Chem, 276 (2001) 47615-47622. 
[51] H. Farhood, N. Serbina, L. Huang, The role of dioleoyl phosphatidylethanolamine in 
cationic liposome mediated gene transfer, Biochim Biophys Acta, 1235 (1995) 289-295. 
[52] M.C. Garnett, Gene-delivery systems using cationic polymers, Crit Rev Ther Drug Carrier 
Syst, 16 (1999) 147-207. 
[53] D.Y. Kwoh, C.C. Coffin, C.P. Lollo, J. Jovenal, M.G. Banaszczyk, P. Mullen, A. Phillips, 
A. Amini, J. Fabrycki, R.M. Bartholomew, S.W. Brostoff, D.J. Carlo, Stabilization of poly-L-
lysine/DNA polyplexes for in vivo gene delivery to the liver, Biochim Biophys Acta, 1444 
(1999) 171-190. 
[54] U.K. Laemmli, Characterization of DNA condensates induced by poly(ethylene oxide) and 
polylysine, Proc Natl Acad Sci U S A, 72 (1975) 4288-4292. 
[55] T.G. Park, J.H. Jeong, S.W. Kim, Current status of polymeric gene delivery systems, Adv 
Drug Deliv Rev, 58 (2006) 467-486. 
[56] O. Boussif, F. Lezoualc'h, M.A. Zanta, M.D. Mergny, D. Scherman, B. Demeneix, J.P. 
Behr, A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: 
polyethylenimine, Proc Natl Acad Sci U S A, 92 (1995) 7297-7301. 
[57] R.V. Benjaminsen, M.A. Mattebjerg, J.R. Henriksen, S.M. Moghimi, T.L. Andresen, The 
possible &quot;proton sponge &quot; effect of polyethylenimine (PEI) does not include change 
in lysosomal pH, Mol Ther, 21 (2013) 149-157. 
[58] J.-P. Behr, The Proton Sponge: a Trick to Enter Cells the Viruses Did Not Exploit, (1997). 
[59] A. Akinc, M. Thomas, A.M. Klibanov, R. Langer, Exploring polyethylenimine-mediated 
DNA transfection and the proton sponge hypothesis, J Gene Med, 7 (2005) 657-663. 
[60] M. Neu, D. Fischer, T. Kissel, Recent advances in rational gene transfer vector design 
based on poly(ethylene imine) and its derivatives, J Gene Med, 7 (2005) 992-1009. 
[61] S. Werth, B. Urban-Klein, L. Dai, S. Hobel, M. Grzelinski, U. Bakowsky, F. Czubayko, 
A. Aigner, A low molecular weight fraction of polyethylenimine (PEI) displays increased 
transfection efficiency of DNA and siRNA in fresh or lyophilized complexes, J Control 
Release, 112 (2006) 257-270. 
 
 94 
 
[62] M. Grzelinski, B. Urban-Klein, T. Martens, K. Lamszus, U. Bakowsky, S. Hobel, F. 
Czubayko, A. Aigner, RNA interference-mediated gene silencing of pleiotrophin through 
polyethylenimine-complexed small interfering RNAs in vivo exerts antitumoral effects in 
glioblastoma xenografts, Hum Gene Ther, 17 (2006) 751-766. 
[63] L.A. Dailey, E. Kleemann, T. Merdan, H. Petersen, T. Schmehl, T. Gessler, J. Hanze, W. 
Seeger, T. Kissel, Modified polyethylenimines as non viral gene delivery systems for aerosol 
therapy: effects of nebulization on cellular uptake and transfection efficiency, J Control 
Release, 100 (2004) 425-436. 
[64] C. Brus, H. Petersen, A. Aigner, F. Czubayko, T. Kissel, Physicochemical and biological 
characterization of polyethylenimine-graft-poly(ethylene glycol) block copolymers as a 
delivery system for oligonucleotides and ribozymes, Bioconjug Chem, 15 (2004) 677-684. 
[65] A. Aigner, D. Fischer, T. Merdan, C. Brus, T. Kissel, F. Czubayko, Delivery of unmodified 
bioactive ribozymes by an RNA-stabilizing polyethylenimine (LMW-PEI) efficiently down-
regulates gene expression, Gene Ther, 9 (2002) 1700-1707. 
[66] C. Brus, H. Petersen, A. Aigner, F. Czubayko, T. Kissel, Efficiency of polyethylenimines 
and polyethylenimine-graft-poly (ethylene glycol) block copolymers to protect 
oligonucleotides against enzymatic degradation, Eur J Pharm Biopharm, 57 (2004) 427-430. 
[67] D. Fischer, T. Bieber, Y. Li, H.P. Elsasser, T. Kissel, A novel non-viral vector for DNA 
delivery based on low molecular weight, branched polyethylenimine: effect of molecular 
weight on transfection efficiency and cytotoxicity, Pharm Res, 16 (1999) 1273-1279. 
[68] T. Merdan, K. Kunath, H. Petersen, U. Bakowsky, K.H. Voigt, J. Kopecek, T. Kissel, 
PEGylation of poly(ethylene imine) affects stability of complexes with plasmid DNA under in 
vivo conditions in a dose-dependent manner after intravenous injection into mice, Bioconjug 
Chem, 16 (2005) 785-792. 
[69] T. Endres, M. Zheng, A. Kılıç, A. Turowska, M. Beck-Broichsitter, H. Renz, O.M. Merkel, 
T. Kissel, Amphiphilic Biodegradable PEG-PCL-PEI Triblock Copolymers for FRET-Capable 
in Vitro and in Vivo Delivery of siRNA and Quantum Dots, (2014). 
[70] T. Merdan, J. Callahan, H. Petersen, K. Kunath, U. Bakowsky, P. Kopeckova, T. Kissel, 
J. Kopecek, Pegylated polyethylenimine-Fab' antibody fragment conjugates for targeted gene 
delivery to human ovarian carcinoma cells, Bioconjug Chem, 14 (2003) 989-996. 
[71] O.M. Merkel, M.A. Mintzer, J. Sitterberg, U. Bakowsky, E.E. Simanek, T. Kissel, Triazine 
dendrimers as non-viral gene delivery systems: Effects of molecular structure on biological 
activity, Bioconjug Chem, 20 (2009) 1799-1806. 
[72] O. Samsonova, C. Pfeiffer, M. Hellmund, O.M. Merkel, T. Kissel, Low Molecular Weight 
pDMAEMA-block-pHEMA Block-Copolymers Synthesized via RAFT-Polymerization: 
Potential Non-Viral Gene Delivery Agents?, Polymers, 3 (2011) 693-718. 
[73] G. Borchard, Chitosans for gene delivery, Adv Drug Deliv Rev, 52 (2001) 145-150. 
 95 
 
[74] J. Haas, M.N. Ravi Kumar, G. Borchard, U. Bakowsky, C.M. Lehr, Preparation and 
characterization of chitosan and trimethyl-chitosan-modified poly-(epsilon-caprolactone) 
nanoparticles as DNA carriers, AAPS PharmSciTech, 6 (2005) E22-30. 
[75] J. Schäfer, S. Hobel, U. Bakowsky, A. Aigner, Liposome-polyethylenimine complexes for 
enhanced DNA and siRNA delivery, Biomaterials, 31 (2010) 6892-6900. 
[76] C. Peetla, A. Stine, V. Labhasetwar, Biophysical interactions with model lipid membranes: 
applications in drug discovery and drug delivery, Mol Pharm, 6 (2009) 1264-1276. 
[77] M. Thomas, J.J. Lu, Q. Ge, C. Zhang, J. Chen, A.M. Klibanov, Full deacylation of 
polyethylenimine dramatically boosts its gene delivery efficiency and specificity to mouse lung, 
Proc Natl Acad Sci U S A, 102 (2005) 5679-5684. 
[78] S.M. Moghimi, P. Symonds, J.C. Murray, A.C. Hunter, G. Debska, A. Szewczyk, A two-
stage poly(ethylenimine)-mediated cytotoxicity: implications for gene transfer/therapy, Mol 
Ther, 11 (2005) 990-995. 
[79] K. Regnström, E.G.E. Ragnarsson, M. Köping-Höggård, E. Torstensson, H. Nyblom, P. 
Artursson, PEI - a potent, but not harmless, mucosal immuno-stimulator of mixed T-helper cell 
response and FasL-mediated cell death in mice, Gene Therapy, 10 (2003) 1575-1583. 
[80] M. Breunig, U. Lungwitz, R. Liebl, A. Goepferich, Breaking up the correlation between 
efficacy and toxicity for nonviral gene delivery, Proc Natl Acad Sci U S A, 104 (2007) 14454-
14459. 
[81] E. Blanco, H. Shen, M. Ferrari, Principles of nanoparticle design for overcoming biological 
barriers to drug delivery, Nature Biotechnology, 33 (2015) 941-951. 
[82] A.P. Dabkowska, D.J. Barlow, A.V. Hughes, R.A. Campbell, P.J. Quinn, M.J. Lawrence, 
The effect of neutral helper lipids on the structure of cationic lipid monolayers, J R Soc 
Interface, 9 (2012) 548-561. 
[83] J. Zabner, A.J. Fasbender, T. Moninger, K.A. Poellinger, M.J. Welsh, Cellular and 
molecular barriers to gene transfer by a cationic lipid, J Biol Chem, 270 (1995) 18997-19007. 
[84] D.E.J.G.J. Dolmans, D. Fukumura, R.K. Jain, Photodynamic therapy for cancer, Nature 
Reviews Cancer, 3 (2003) 380-387. 
[85] T.J. Dougherty, C.J. Gomer, B.W. Henderson, G. Jori, D. Kessel, M. Korbelik, J. Moan, 
Q. Peng, Photodynamic therapy, J Natl Cancer Inst, 90 (1998) 889-905. 
[86] F. Stewart, P. Baas, W. Star, What does photodynamic therapy have to offer radiation 
oncologists (or their cancer patients)?, Radiother Oncol, 48 (1998) 233-248. 
[87] P.J. Lou, H.R. Jager, L. Jones, T. Theodossy, S.G. Bown, C. Hopper, Interstitial 
photodynamic therapy as salvage treatment for recurrent head and neck cancer, Br J Cancer, 91 
(2004) 441-446. 
 
 96 
 
[88] C. Pais-Silva, D. de Melo-Diogo, I.J. Correia, IR780-loaded TPGS-TOS micelles for breast 
cancer photodynamic therapy, European Journal of Pharmaceutics and Biopharmaceutics, 113 
(2017) 108-117. 
[89] M.A. Biel, Photodynamic therapy of head and neck cancers, Methods Mol Biol, 635 (2010) 
281-293. 
[90] P.K. Selbo, A. Hogset, L. Prasmickaite, K. Berg, Photochemical internalisation: a novel 
drug delivery system, Tumour Biol, 23 (2002) 103-112. 
[91] K. Berg, M. Folini, L. Prasmickaite, P.K. Selbo, A. Bonsted, B.O. Engesaeter, N. 
Zaffaroni, A. Weyergang, A. Dietze, G.M. Maelandsmo, E. Wagner, O.J. Norum, A. Hogset, 
Photochemical internalization: a new tool for drug delivery, Curr Pharm Biotechnol, 8 (2007) 
362-372. 
[92] K. Berg, A. Weyergang, L. Prasmickaite, A. Bonsted, A. Hogset, M.T. Strand, E. Wagner, 
P.K. Selbo, Photochemical internalization (PCI): a technology for drug delivery, Methods Mol 
Biol, 635 (2010) 133-145. 
[93] T. Ohtsuki, S. Miki, S. Kobayashi, T. Haraguchi, E. Nakata, K. Hirakawa, K. Sumita, K. 
Watanabe, S. Okazaki, The molecular mechanism of photochemical internalization of cell 
penetrating peptide-cargo-photosensitizer conjugates, Scientific Reports, Published online: 21 
December 2015; | doi:10.1038/srep18577, (2015). 
[94] M.J. Shieh, C.L. Peng, P.J. Lou, C.H. Chiu, T.Y. Tsai, C.Y. Hsu, C.Y. Yeh, P.S. Lai, Non-
toxic phototriggered gene transfection by PAMAM-porphyrin conjugates, J Control Release, 
129 (2008) 200-206. 
[95] A. Puri, Phototriggerable Liposomes: Current Research and Future Perspectives, 
Pharmaceutics, 6 (2014) 1-25. 
[96] P. Shum, J.M. Kim, D.H. Thompson, Phototriggering of liposomal drug delivery systems, 
Adv Drug Deliv Rev, 53 (2001) 273-284. 
[97] M. Folini, K. Berg, E. Millo, R. Villa, L. Prasmickaite, M.G. Daidone, U. Benatti, N. 
Zaffaroni, Photochemical internalization of a peptide nucleic acid targeting the catalytic subunit 
of human telomerase, Cancer Res, 63 (2003) 3490-3494. 
[98] A. Ndoye, J.L. Merlin, A. Leroux, G. Dolivet, P. Erbacher, J.P. Behr, K. Berg, F. 
Guillemin, Enhanced gene transfer and cell death following p53 gene transfer using 
photochemical internalisation of glucosylated PEI-DNA complexes, J Gene Med, 6 (2004) 884-
894. 
[99] I. Donald, J. Macvicar, T.G. Brown, Investigation Of Abdominal Masses By Pulsed 
Ultrasound, The Lancet, 271 (1958) 1188-1195. 
[100] D.E. FitzGerald, J.E. Drumm, Non-invasive measurement of human fetal circulation 
using ultrasound: a new method., (1977). 
[101] P. Freeman, The role of ultrasound in the assessment of the trauma patient, Aust J Rural 
Health, 7 (1999) 85-89. 
 97 
 
[102] W.G. Pitt, G.A. Husseini, B.J. Staples, Ultrasonic Drug Delivery – A General Review, 
Expert Opin Drug Deliv, 1 (2004) 37-56. 
[103] C. Olbrich, P. Hauff, F. Scholle, W. Schmidt, U. Bakowsky, A. Briel, M. Schirner, The 
in vitro stability of air-filled polybutylcyanoacrylate microparticles, Biomaterials, 27 (2006) 
3549-3559. 
[104] J. Brussler, E. Marxer, A. Becker, R. Schubert, J. Schummelfeder, C. Nimsky, U. 
Bakowsky, Correlation of structure and echogenicity of nanoscaled ultrasound contrast agents 
in vitro, Colloids Surf B Biointerfaces, 117 (2014) 206-215. 
[105] S. Mitragotri, Healing sound: the use of ultrasound in drug delivery and other therapeutic 
applications, Nature Reviews Drug Discovery, 4 (2005) 255-260. 
[106] M. Joersbo, J. Brunstedt, Sonication: A new method for gene transfer to plants, 
Physiologia Plantarum, 85 (1992) 230-234. 
[107] J. Sundaram, B.R. Mellein, S. Mitragotri, An Experimental and Theoretical Analysis of 
Ultrasound-Induced Permeabilization of Cell Membranes, in:  Biophys J, 2003, pp. 3087-3101. 
[108] A. Rahim, S.L. Taylor, N.L. Bush, G.R. ter Haar, J.C. Bamber, C.D. Porter, Physical 
parameters affecting ultrasound/microbubble-mediated gene delivery efficiency in vitro, 
Ultrasound Med Biol, 32 (2006) 1269-1279. 
[109] N. Nomikou, A.P. McHale, Microbubble-enhanced ultrasound-mediated gene transfer--
towards the development of targeted gene therapy for cancer, Int J Hyperthermia, 28 (2012) 
300-310. 
[110] S. Wirtz, M.F. Neurath, Gene transfer approaches for the treatment of inflammatory 
bowel disease, Gene Therapy, 10 (2003) 854-860. 
[111] S.W. Tas, M.J. Vervoordeldonk, P.P. Tak, Gene Therapy Targeting Nuclear Factor-κB: 
Towards Clinical Application in Inflammatory Diseases and Cancer, Curr Gene Ther, 9 (2009) 
160-170. 
[112] T. Collins, A. Williams, G.I. Johnston, J. Kim, R. Eddy, T. Shows, M.A. Gimbrone, Jr., 
M.P. Bevilacqua, Structure and chromosomal location of the gene for endothelial-leukocyte 
adhesion molecule 1, J Biol Chem, 266 (1991) 2466-2473. 
[113] V. Kumar, R.S. Cotran, T. Collins, S.L. Robbins, Robbins Pathological Basis of Disease., 
7th ed., WB Saunders, Philadelphia, PA, 1999. 
[114] G.L. Nicolson, Cancer metastasis: tumor cell and host organ properties important in 
metastasis to specific secondary sites, Biochim Biophys Acta, 948 (1988) 175-224. 
[115] K. K.J., V. T.K., Isotherms of Dipalmitoylphosphatidylcholine (DPPC) Monolayers: 
Features Revealed and Features Obscured - ScienceDirect, Journal of Colloid and Interface 
Science, (1996). 
[116] B.d. Kruijff, P.R. Cullis, A.J. Verkleij, Non-bilayer lipid structures in model and 
biological membranes, Trends in Biochemical Sciences, 5 (1980) 79-81. 
 98 
 
[117] I. Wrobel, D. Collins, Fusion of cationic liposomes with mammalian cells occurs after 
endocytosis, Biochim Biophys Acta, 1235 (1995) 296-304. 
[118] G. Bastiat, M. Lafleur, Phase Behavior of Palmitic Acid/Cholesterol/Cholesterol Sulfate 
Mixtures and Properties of the Derived Liposomes, The Journal of Physical Chemistry B, 
(2007). 
[119] K. Crook, B.J. Stevenson, M. Dubouchet, D.J. Porteous, Inclusion of cholesterol in 
DOTAP transfection complexes increases the delivery of DNA to cells in vitro in the presence 
of serum, Gene Ther, 5 (1998) 137-143. 
[120] D.S. Zhuk, P.A. Gembitskii, V.A. Kargin, Advances in the chemistry of 
Polyethyleneimine (Polyaziridine), Russian Chemical Reviews, 34 (1965) 515-527. 
[121] I.M. Klotz, G.P. Royer, I.S. Scarpa, Synthetic derivatives of polyethyleneimine with 
enzyme-like catalytic activity (synzymes), Proc Natl Acad Sci U S A, 68 (1971) 263-264. 
[122] S. Fiedler, R. Wirth, Transformation of bacteria with plasmid DNA by electroporation, 
Anal Biochem, 170 (1988) 38-44. 
[123] C.J. Edgell, C.C. McDonald, J.B. Graham, Permanent cell line expressing human factor 
VIII-related antigen established by hybridization, Proc Natl Acad Sci U S A, 80 (1983) 3734-
3737. 
[124] Biological evaluation of medical devices Part 5: Tests for in vitro cytotoxicity, in:  IS0  
10  993-5,  EN  30  993-5,  199, 2009. 
[125] British Standard Institution Evaluation of medical devices for biological hazards part 10., 
in:  BS 5736: part 1, 1988. 
[126] R. Zange, T. Kissel, Comparative in vitro biocompatibility testing of polycyanoacrylates 
and poly(d,l-lactide-co-glycolide) using different mouse fibroblast (L929) biocompatibility test 
models, European Journal of Pharmaceutics and Biopharmaceutics, 44 (1997) 149-157. 
[127] C.D. Scher, M.U. Hematology-Oncology Division Children's Hospital Medical Center 
Boston, M.U. Sidney Farber Cancer Center Department of Pediatrics Harvard Medical School 
Boston, C. Haudenschild, M. Klagsbrun, The chick chorioallantoic membrane as a model 
system for the study of tissue invasion by viral transformed cells, Cell, 8 (1976) 373-382. 
[128] D. Ribatti, A. Gualandris, M. Bastaki, A. Vacca, M. Iurlaro, L. Roncali, M. Presta, New 
model for the study of angiogenesis and antiangiogenesis in the chick embryo chorioallantoic 
membrane: the gelatin sponge/chorioallantoic membrane assay, J Vasc Res, 34 (1997) 455-463. 
[129] J. Jedelska, B. Strehlow, U. Bakowsky, A. Aigner, S. Hobel, M. Bette, M. Roessler, N. 
Franke, A. Teymoortash, J.A. Werner, B. Eivazi, R. Mandic, The chorioallantoic membrane 
assay is a promising ex vivo model system for the study of vascular anomalies, In Vivo, 27 
(2013) 701-705. 
[130] W. Guo, R.J. Lee, Receptor-targeted gene delivery viafolate-conjugated 
polyethylenimine, AAPS PharmSci, 1 (1999) 20-26. 
 99 
 
[131] V. Bonasera, S. Alberti, A. Sacchetti, Protocol for high-sensitivity/long linear-range 
spectrofluorimetric DNA quantification using ethidium bromide, Biotechniques, 43 (2007) 
173-174, 176. 
[132] R.L. Steere, Electron microscopy of structural detail in frozen biological specimens, J 
Biophys Biochem Cytol, 3 (1957) 45-60. 
[133] L. Duse, Untersuchungen einer Prototyp LED-Leuchte zur Photodynamischen Therapie 
mit photosensibilisator-haltigen Liposomen, in:  Department of Pharmaceutics and 
Biopharmaceutics, Technische Hochschule Mittelhessen, Gießen, 2016. 
[134] P.K. Smith, R.I. Krohn, G.T. Hermanson, A.K. Mallia, F.H. Gartner, M.D. Provenzano, 
E.K. Fujimoto, N.M. Goeke, B.J. Olson, D.C. Klenk, Measurement of protein using 
bicinchoninic acid, Anal Biochem, 150 (1985) 76-85. 
[135] M.P. Bevilacqua, J.S. Pober, D.L. Mendrick, R.S. Cotran, M.A. Gimbrone, Identification 
of an inducible endothelial-leukocyte adhesion molecule, Proc Natl Acad Sci U S A, 84 (1987) 
9238-9242. 
[136] T. Mosmann, Rapid colorimetric assay for cellular growth and survival: Application to 
proliferation and cytotoxicity assays, 65 (1983) 55–63. 
[137] M. Wintrobe, Wintrobe's Clinical Hematology, 9 ed., Lea & Febiger, Philadelphia, 1993. 
[138] R. Duncan, M. Bhakoo, M.-L. Riley, A. Tuboku-Metzger, Soluble Polymeric Drug 
Carriers: Haematocompatibility, Birkhäuser, Basel, 1991. 
[139] A. Ozcetin, A. Aigner, U. Bakowsky, A chorioallantoic membrane model for the 
determination of anti-angiogenic effects of imatinib, Eur J Pharm Biopharm, 85 (2013) 711-
715. 
[140] I.M. Tucker, J.C.W. Corbett, J. Fatkin, R.O. Jack, M. Kaszuba, B. MacCreath, F. McNeil-
Watson, Laser Doppler Electrophoresis applied to colloids and surfaces, Colloids and Surfaces: 
A, 20 (2015) 215-226. 
[141] D. Goula, J.S. Remy, P. Erbacher, M. Wasowicz, G. Levi, B. Abdallah, B.A. Demeneix, 
Size, diffusibility and transfection performance of linear PEI/DNA complexes in the mouse 
central nervous system, Gene Ther, 5 (1998) 712-717. 
[142] A. von Harpe, H. Petersen, Y. Li, T. Kissel, Characterization of commercially available 
and synthesized polyethylenimines for gene delivery, J Control Release, 69 (2000) 309-322. 
[143] M.J. Hope, R. Nayar, L.D. Mayer, P.R. Cullis, Reduction of Liposome Size and 
Preparation of Unilamellar Vesicles by Extrusion Techniques, in: G. Gregoriadis (Ed.) 
Liposome Technology, CRC Press, 1993. 
[144] N. Duzgunes, Liposomes, Part D, 1 ed., Academic Press, 2004. 
[145] I. Mellman, Endocytosis and molecular sorting, Annu Rev Cell Dev Biol, 12 (1996) 575-
625. 
 100 
 
[146] T.W. Prow, W.A. Rose, N. Wang, L.M. Reece, Y. Lvov, J.F. Leary, T. Vo-Dinh, W.S. 
Grundfest, D.A. Benaron, G.E. Cohn, Biosensor-controlled gene therapy/drug delivery with 
nanoparticles for nanomedicine, Advanced Biomedical and Clinical Diagnostic Systems III, 
5692 (2005) 199. 
[147] A. Rolland, S.M. Sullivan, Pharmaceutical Gene Delivery Systems (Drugs and the 
Pharmaceutical Sciences), 1 ed., CRC Press, 2003. 
[148] D. Fischer, Y. Li, B. Ahlemeyer, J. Krieglstein, T. Kissel, In vitro cytotoxicity testing of 
polycations: influence of polymer structure on cell viability and hemolysis, Biomaterials, 24 
(2003) 1121-1131. 
[149] V. Pector, J. Backmann, D. Maes, M. Vandenbranden, J.M. Ruysschaert, Biophysical and 
structural properties of DNA.diC(14)-amidine complexes. Influence of the DNA/lipid ratio, J 
Biol Chem, 275 (2000) 29533-29538. 
[150] H. Lodish, A. Berk, S.L. Zipursky, P. Matsudaira, D. Baltimore, J. Darnell, 
Biomembranes: Structural Organization and Basic Functions, in:  Molecular Cell Biology, W. 
H. Freeman, 2000. 
[151] J. Schaefer, C. Schulze, E.E. Marxer, U.F. Schaefer, W. Wohlleben, U. Bakowsky, C.M. 
Lehr, Atomic force microscopy and analytical ultracentrifugation for probing nanomaterial 
protein interactions, ACS Nano, 6 (2012) 4603-4614. 
[152] J. Sitterberg, A. Ozcetin, C. Ehrhardt, U. Bakowsky, Utilising atomic force microscopy 
for the characterisation of nanoscale drug delivery systems, Eur J Pharm Biopharm, 74 (2010) 
2-13. 
[153] H. Engelberg, Plasma heparin levels. Correlation with serum cholesterol and low-density 
lipoproteins, Circulation, 23 (1961) 573-577. 
[154] A.L. Parker, D. Oupicky, P.R. Dash, L.W. Seymour, Methodologies for monitoring 
nanoparticle formation by self-assembly of DNA with poly(l-lysine), Anal Biochem, 302 
(2002) 75-80. 
[155] J.W. Wiseman, C.A. Goddard, D. McLelland, W.H. Colledge, A comparison of linear 
and branched polyethylenimine (PEI) with DCChol/DOPE liposomes for gene delivery to 
epithelial cells in vitro and in vivo, Gene Therapy, 10 (2003) 1654-1662. 
[156] M. Emerson, L. Renwick, S. Tate, S. Rhind, E. Milne, H.A. Painter, A.C. Boyd, G. 
McLachlan, U. Griesenbach, S.H. Cheng, D.R. Gill, S.C. Hyde, A. Baker, E.W. Alton, D.J. 
Porteous, D.D. Collie, Transfection efficiency and toxicity following delivery of naked plasmid 
DNA and cationic lipid-DNA complexes to ovine lung segments, Mol Ther, 8 (2003) 646-653. 
[157] A. Raup, V. Jérôme, R. Freitag, C.V. Synatschke, A.H.E. Müller, Promoter, transgene, 
and cell line effects in the transfection of mammalian cells using PDMAEMA-based nano-stars, 
Biotechnology Reports, 11 (2016) 53-61. 
[158] O.L. Mozley, A Mechanistic Dissection of Polyethylenimine Mediated Transfection of 
Chinese Hamster Ovary Cells, (2013). 
 101 
 
[159] N.P. Gabrielson, D.W. Pack, Efficient polyethylenimine-mediated gene delivery 
proceeds via a caveolar pathway in HeLa cells, J Control Release, 136 (2009) 54-61. 
[160] A.I. Ivanov, Pharmacological inhibition of endocytic pathways: is it specific enough to 
be useful?, Methods Mol Biol, 440 (2008) 15-33. 
[161] N. Oh, J.H. Park, Endocytosis and exocytosis of nanoparticles in mammalian cells, Int J 
Nanomedicine, 9 (2014) 51-63. 
[162] A. Hogset, L. Prasmickaite, P.K. Selbo, M. Hellum, B.O. Engesaeter, A. Bonsted, K. 
Berg, Photochemical internalisation in drug and gene delivery, Adv Drug Deliv Rev, 56 (2004) 
95-115. 
[163] M. Tomizawa, F. Shinozaki, Y. Motoyoshi, T. Sugiyama, S. Yamamoto, M. Sueishi, 
Sonoporation: Gene transfer using ultrasound, World J Methodol, 3 (2013) 39-44. 
[164] E.C. Unger, E. Hersh, M. Vannan, T.O. Matsunaga, T. McCreery, Local drug and gene 
delivery through microbubbles, Prog Cardiovasc Dis, 44 (2001) 45-54. 
[165] G. ter Haar, Ultrasonic imaging: safety considerations, in:  Interface Focus, 2011, pp. 
686-697. 
[166] D. Omata, Y. Negishi, S. Yamamura, S. Hagiwara, Y. Endo-Takahashi, R. Suzuki, K. 
Maruyama, M. Nomizu, Y. Aramaki, Involvement of Ca(2)(+) and ATP in enhanced gene 
delivery by bubble liposomes and ultrasound exposure, Mol Pharm, 9 (2012) 1017-1023. 
[167] D.J. Gary, N. Puri, Y.Y. Won, Polymer-based siRNA delivery: perspectives on the 
fundamental and phenomenological distinctions from polymer-based DNA delivery, J Control 
Release, 121 (2007) 64-73. 
[168] S.R. Barthel, J.D. Gavino, L. Descheny, C.J. Dimitroff, Targeting selectins and selectin 
ligands in inflammation and cancer, Expert Opin Ther Targets, 11 (2007) 1473-1491. 
[169] N. Matsuura, T. Narita, C. Mitsuoka, N. Kimura, R. Kannagi, T. Imai, H. Funahashi, H. 
Takagi, Increased concentration of soluble E-selectin in the sera of breast cancer patients, 
Anticancer Res, 17 (1997) 1367-1372. 
[170] T. Narita, N. Kawakami-Kimura, N. Matsuura, J. Hosono, R. Kannagi, Corticosteroids 
and medroxyprogesterone acetate inhibit the induction of E-selectin on the vascular 
endothelium by MDA-MB-231 breast cancer cells, Anticancer Res, 15 (1995) 2523-2527. 
[171] U. Bakowsky, G. Schumacher, C. Gege, R.R. Schmidt, U. Rothe, G. Bendas, Cooperation 
between lateral ligand mobility and accessibility for receptor recognition in selectin-induced 
cell rolling, Biochemistry, 41 (2002) 4704-4712. 
[172] B. Carneiro, A.C. Braga, M.N. Batista, M. Harris, P. Rahal, Evaluation of canonical 
siRNA and Dicer substrate RNA for inhibition of hepatitis C virus genome replication--a 
comparative study, PLoS One, 10 (2015) e0117742. 
[173] D.J. Foster, S. Barros, R. Duncan, S. Shaikh, W. Cantley, A. Dell, E. Bulgakova, J. 
O'Shea, N. Taneja, S. Kuchimanchi, C.B. Sherrill, A. Akinc, G. Hinkle, A.C. Seila White, B. 
 102 
 
Pang, K. Charisse, R. Meyers, M. Manoharan, S.M. Elbashir, Comprehensive evaluation of 
canonical versus Dicer-substrate siRNA in vitro and in vivo, RNA, 18 (2012) 557-568. 
[174] V. Kafil, Y. Omidi, Cytotoxic Impacts of Linear and Branched Polyethylenimine 
Nanostructures in A431 Cells, Bioimpacts, 1 (2011) 23-30. 
[175] M.S. Shim, Y.J. Kwon, Acid-Responsive Linear Polyethylenimine for Efficient, Specific, 
and Biocompatible siRNA Delivery, Bioconjugate Chemistry, (2009). 
[176] G.E. Deibler, M.S. Holmes, P.L. Campbell, J. Gans, Use of triton X-100 as a hemolytic 
agent in the spectrophotometric measurement of blood O2 saturation, J Appl Physiol, 14 (1959) 
133-136. 
[177] J.G. Lenahan, S. Frye, G.E. Phillips, Use of the Activated Partial Thromboplastin Time 
in the Control of Heparin Administration, Clinical Chemistry, 12 (1966) 263-268. 
[178] P. Nowak-Sliwinska, T. Segura, M.L. Iruela-Arispe, The chicken chorioallantoic 
membrane model in biology, medicine and bioengineering, Angiogenesis, 17 (2014) 779-804. 
[179] A. Vargas, M. Zeisser-Labouebe, N. Lange, R. Gurny, F. Delie, The chick embryo and 
its chorioallantoic membrane (CAM) for the in vivo evaluation of drug delivery systems, Adv 
Drug Deliv Rev, 59 (2007) 1162-1176. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 103 
 
5.2 List of abbreviations 
AFM    Atomic Force Microscopy 
AGO    Argonuate 
aPTT    Activated Partial Thromboplastin Time  
EDD    Egg Development Day 
BCA    Bicinchoninic Acid 
bp    Base Pairs 
bPEI    Branched PEI 
CAM    Chorioallantoic Membrane 
CCD    Charged Coupled Device 
CLSM    Confocal Laser Scanning Microscopy 
CMOS    Complementary Metal-Oxide-Semiconductor 
CMV    Cytomegalovirus  
DAPI    4',6-diamidino-2-phenylindole 
DDC    DOPE, DPPC, Cholesterol  
DLS    Dynamic Light Scattering 
DMEM   Dulbecco’s Modified Eagle’s Medium 
DMRIE   1,2-dimyristyloxy-propyl-3-dimethyl-hydroxy ethyl ammonium 
    bromide 
 
DMSO   Dimethylsulphoxide 
DNA     Deoxyribonucleic Acid  
DODC    DOTAP, DPPC, Cholesterol 
DOGS    1,2-di-(9Z-octadecenoyl)-sn-glycero-3- [(N- (5-amino-1- 
    carboxypentyl) iminodiacetic acid) succinyl 
 
DOPE    1,2-dioleoyl-sn-glycero-3-phosphoethanolamine 
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DOTAP   1,2-dioleoyl-3-trimethylammonium-propane 
DOTIM   (1-[2-(9-(Z)-octadecenoyloxy)ethyl] -2-(8-(Z)-heptadecenyl) -3 
    (hydroxyethyl) imidazolinium chloride 
 
DOTMA   1,2-di-O-octadecenyl-3-trimethylammonium propane 
 
DPPC    Dipalmitoylphosphatidylcholine 
dsiRNA   Dicer Substrate Short Interfering Ribonucleic Acid 
EGF    Endothelial Growth Factor 
EGFP    Enhanced Green Fluorescence Protein 
ELISA    Enzyme-Linked Immunosorbent Assay 
EMA    European Medicines Agency 
FDA    Food and Drug Administration 
FGF    Fibroblast Growth Factor 
GFP    Green Fluorescence Protein 
HeNe    Helium Neon 
HEPES   4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid 
HRP    Horseradish Peroxidase 
HT-DNA   Herring Testes deoxyribonucleic acid 
IGF    Insulin-Like Growth Factor 
IMDM    Iscove’s Modified Dulbecco’s Medium 
IU    International Units 
LDH    Lactate Dehydrogenase 
LDV    Laser Doppler Velocimetry 
LED    Light Emitting Diode  
lPEI    Linear Polyethylenimine  
LPP    Lipopolyplex 
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MCDB   Molecular, Cellular and Developmental Biology (medium) 
MI    Mechanical Index 
mRNA   Messenger Ribonucleic Acid 
MTT    3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide 
OD    Optical Density 
PAMAM   Polyamidoamine 
PBS    Phosphate Buffered Saline  
PCI    Photochemical Internalisation 
PDI    Polydispersity Index  
pDMAEMA   Poly (2-dimethylaminoethyl methacrylate) 
pDNA    Plasmid Deoxyribonucleic Acid 
PDT    Photodynamic Therapy 
PEG    Polyethylene Gylcol 
PEI    Polyethylenimine 
PLGA    Poly (lactic-co-glycolic acid) 
PLL    Poly-L-lysine 
PP    Polyplex 
RISC    Ribonucleic Acid Induced Silencing Complex 
RLU    Relative Luminescence Units 
RNA    Ribonucleic Acid 
RNAi    Ribonucleic Acid Interference 
RT    Room Temperature 
SAINT   N-methyl-4(dioleyl)methylpyridiniumchloride 
SD    Standard Deviation 
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SELE    E-selectin  
SEM    Scanning Electron Microscope 
siCtrl    Control Short Interfering Ribonucleic Acid 
siRNA    Short Interfering Ribonucleic Acid 
SOC    Super Optimal Broth with Catabolite Repression 
TBE    Tris(hydroxymethyl)aminomethane/Borate/   
    Ethylenediaminetetraacetic acid 
 
TEM    Transmission Electron Microscope 
TNF    Tumour Necrosis Factor 
Tris    Tris(hydroxymethyl)aminomethane 
UEGT    Ultrasound Enhanced Gene Transfer 
VEGF    Vascular Endothelial Growth Factor 
WD    Working Distance 
 
 
 
 
 
 
 107 
 
5.3 Research output 
1.) L. Duse, S.R. Pinnapireddy, B. Strehlow, J. Jedelská, U. Bakowsky; Can Curcumin loaded  
Liposomes together with LED’s improve the quality of Photodynamic Therapy? Submitted 
manuscript 
 
2.) E. Baghdan, S. R. Pinnapireddy, B. Strehlow, K. Engelhardt, J. Schäfer, U. Bakowsky; 
Lipid coated Chitosan-DNA nanoparticles for enhanced gene delivery. Submitted manuscript; 
Equally contributing author 
 
3.) M. Möhwald, S. R. Pinnapireddy, B. Wonnenberg, M. Pourasghar, M.Jurisic, A. Jung, C. 
F. Straube, T. Tschernig, U. Bakowsky, M. Schneider; Aspherical, Nanostructured 
Microparticles for Targeted Gene Delivery to Alveolar Macrophages. Submitted Manuscript; 
Equally contributing author 
 
4.) S.R. Pinnapireddy, L. Duse, B. Strehlow, J. Schäfer, U. Bakowsky; Composite liposome-
PEI/nucleic acid lipopolyplexes for safe and efficient gene delivery and gene knockdown. 
Submitted Manuscript, under consideration.  
 
5.) F. Yang, R. Riedel, P. Pino, B. Pelaz, A.H. Said, M. Soliman, S.R. Pinnapireddy, N. Feliu, 
W.J. Parak, U. Bakowsky, N. Hampp; Real-time, label-free monitoring of cell viability based 
on cell adhesion measurements with an atomic force microscope, Journal of 
Nanobiotechnology, 15 (2017) 23. 
 
6.) K.H. Engelhardt, S.R. Pinnapireddy, E. Baghdan, J. Jedelská, U. Bakowsky, Transfection 
Studies with Colloidal Systems Containing Highly Purified Bipolar Tetraether Lipids from 
Sulfolobus acidocaldarius, Archaea, 2017 (2017). 
 
7.) C. Janich, S.R. Pinnapireddy, F. Erdmann, T. Groth, A. Langner, U. Bakowsky, C. Wolk; 
Fast therapeutic DNA internalization - A high potential transfection system based on a peptide 
mimicking cationic lipid, Eur J Pharm Biopharm, (2016). 
 
8.) A. Ewe, O. Panchal, S.R. Pinnapireddy, U. Bakowsky, S. Przybylski, A. Temme, A. 
Aigner; Liposome-polyethylenimine complexes (DPPC-PEI lipopolyplexes) for therapeutic 
siRNA delivery in vivo, Nanomedicine, (2016). 
 
9.) B. Strehlow, U. Bakowsky, S.R. Pinnapireddy, J. Kusterer, G. Mielke, M. Keusgen; A 
Novel Microparticulate Formulation with Allicin In Situ Synthesis, Journal of Pharmaceutics 
& Drug Delivery Research, 2016 (2016). 
 
 
 108 
 
5.4 Presentations 
1.) Next Generation Nanocarriers & Future Trends in Gene Therapy - Lecture: Shashank R. 
Pinnapireddy; Special Session, Controlled Release Society, German Chapter (2nd - 3rd March 
2017), Marburg, Germany.  
2.) Photo-enhanced gene delivery using composite lipopolyplexes - Poster Presentation: 
Shashank R. Pinnapireddy, Lili Duse, Udo Bakowsky; Controlled Release Society, German 
Chapter (2nd - 3rd March 2017), Marburg, Germany. 
3.) Gene delivery using non-viral vectors - Lecture: Shashank R. Pinnapireddy; Department 
of Pharmaceutical Chemistry, AG Steinmetzer Lab (18th January 2017), Marburg, Germany. 
4.) Photo-enhanced gene delivery using curcumin embedded composite lipopolyplexes -  Oral 
Presentation: Shashank R. Pinnapireddy; GPEN (9th - 12th November 2016), Lawrence, USA. 
5.) Ultrafection - a novel liposomal based biophysicochemical gene delivery strategy for safe 
and efficient gene transfer - Oral Presentation: Shashank R. Pinnapireddy; 24th Mountain 
Sea Liposome Workshop (5th - 9th October 2015), Ameland, Netherlands. 
6.) RNAi and gene delivery mediated via novel Lipopolyplexes - Poster Presentation: 
Shashank R. Pinnapireddy, Boris Strehlow, Jens Schäfer, Udo Bakowsky; Controlled Release 
Society Annual Meeting (26th - 29th July 2015), Edinburgh, Scotland. 
7.) Gene Delivery and Knockdown using Novel Lipopolyplexes - Poster Presentation: 
Shashank R. Pinnapireddy, Udo Bakowsky; DPhG Jahrestagung (24th - 26th September 2014), 
Frankfurt, Germany. 
8.) Novel Lipopolyplexes for Gene delivery and Gene knockdown - Poster presentation: 
Shashank R. Pinnapireddy, Udo Bakowsky; GPEN (24th - 30th August 2014), Helsinki, 
Finland.  
 
 
 109 
 
5.5 Curriculum Vitae 
PERSONAL DETAILS 
 
Name    Shashank Reddy Pinnapireddy 
Date of Birth   23 February 1990 
Place of Birth   Hyderabad, India 
Marital Status   Unmarried 
Nationality   Indian 
 
 
EDUCATION AND TRAINING 
 
Mar 2017 - Present  Project Leader, Genetic Engineering and Biosafety 
    Dept. of Pharmaceutics and Biopharmaceutics,  
    University of Marburg, Marburg (Germany) 
 
Mar 2016 - Present  Group Leader, Gene Therapy 
    Dept. of Pharmaceutics and Biopharmaceutics,  
    University of  Marburg, Marburg (Germany) 
 
Aug 2013 - Present  PhD 
    Dept. of Pharmaceutics and Biopharmaceutics,  
    University of  Marburg, Marburg (Germany) 
 
Oct 2011 - Jul 2013  Master of Engineering, Biomedical Engineering 
    University of Halle/Anhalt University of Applied Sciences,  
    Halle an der Saale (Germany)  
 
Mar 2011 - Apr 2011  Internship 
    Aurobindo Pharma Ltd., Hyderabad (India) 
 
Oct 2007 - Jun 2011  Bachelor of Pharmacy 
    Jawaharlal Nehru Technological University, Hyderabad (India) 
 
 
SCHOOLING 
 
Jun 2005 - Apr 2007  Intermediate Education  
    Board of Intermediate Education, Hyderabad (India) 
 
Jun 2001 - Apr 2005   Secondary Education  
    St. Patrick’s High School (SSC Board), Secunderabad (India) 
 
